

Ref. No.: F.02(377)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2023/921 Dated :-11.05.2023

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
(A Govt. of Rajasthan Undertaking)
Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005,
India
Tel No: 0141-2228066, 2228064, E-mail: edprmsc@rajasthan.gov.in

**E-BID FOR THE RATE CONTRACT CUM EMPANELMENT OF
ANALYTICAL TESTING LABORATORIES FOR THE TEST
AND ANALYSIS OF DRUGS
(Two Years RC ending on 30.06.2025)**



!! सर्वे सन्तु निरामया:!!

LAST DATE OF SUBMISSION OF ONLINE BIDS	30.05.2023 & 6.00 PM
DATE AND TIME OF OPENING OF ONLINE TECHNICAL BIDS	31.05.2023 & 11.00 AM

RAJASTHAN MEDICAL SERVICES CORPORATION LTD.

(A Govt. of Rajasthan Undertaking)

Gandhi Block, Swasthya Bhawan, Tilak Marg, Jaipur – 302005, India

Phone No: 0141-2228066, 2228064

Website: www.rmsc.health.rajasthan.gov.in

CIN:U24232RJ2011SGC035067

E-mail : edprmsc@rajasthan.gov.in

Ref. No.: F.02(377)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2023/921 Dated :-11.05.2023

Notice Inviting E-Bids

E-bids are invited up to 6.00 PM of 30.05.2023 from approved Drugs Testing Laboratories situated in India for analysis of Drugs. (Ending on **30.06.2025**).

Details of NIB may be seen at the website of State Public procurement Portal <http://sppp.rajasthan.nic.in>, <http://eproc.rajasthan.gov.in>, <http://rmsc.health.rajasthan.gov.in> and may be downloaded from there.

UBN.No **MSC2324SLRC00017**

**Executive Director (Procurement)
RMSCL**

**RAJASTHAN MEDICAL SERVICES CORPORATION
LTD. RAJASTHAN**

**e-BID FOR RATE CONTRACT CUM EMPANELMENT OF
ANALYTICAL TESTING LABORATORIES FOR THE TEST
AND ANALYSIS OF DRUGS**

(Rate contract for two years ending on 30.06.2025)

Bid Reference	:	F.02(377)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2023/ 921 Dated :- 11.05.2023
Pre- bid conference	:	16.05.2023 at 12.30 P.M.
Date and time for downloading bid document	:	11.05.2023 from 06.00 PM
Last date and time of submission of online bids	:	30.05.2023 at 6.00 PM
Date and time of opening of Online technical bids	:	31.05.2023 at 11.00 PM
Cost of the Bid Document	:	Rs. 2360/- (Including GST@ 18%)
RISL Processing Fees	:	Rs. 2950/- (Including GST @ 18%)
Bid Security	:	Rs. 20000/-

**RAJASTHAN MEDICAL SERVICES CORPORATION LTD.
RAJASTHAN**

**E-BID FOR RATE CONTRACT CUM EMPANELMENT OF
ANALYTICAL TESTING LABORATORIES FOR THE TEST
AND ANALYSIS OF DRUGS (Rate contract for two years ending on
30.06.2025)**

“CONFIDENTIALITY IS THE ESSENCE OF THIS BID”

**1. LAST DATE FOR RECEIPT OF BIDS, BID FORM FEES, BID SECURITY
& RISL PROCESSING FEES**

- a) E-Bids [In Two Separate Bids (Technical Bid & Price Bid)] Shall Be Received Till 06.00 PM on 30.05.2023 By The Rajasthan Medical Services Corporation Ltd, For The Rate contract cum Empanelment Of Analytical Testing Laboratories For The Test And Analysis Of DRUGS (Rate contract for two years ending on **30.06.2025**) in English language. Proposal received after the closing date and time shall not be considered.
- b) The bids shall be valid for a Period of 120 days from the date of opening of Technical Bid and prior to the expiration of the bid validity the Bid Inviting Authority may request the Bidders to extend the bid validity for another period of 30 days. The Bidder may refuse extension of bid validity without forfeiting the Bid Security deposit. No refund of tender fee is claimable under any circumstances to any of the bidder.
- c) The e-Bids will be received on web-portal of e-procurement of GoR i.e. <http://eproc.rajasthan.gov.in>. Every Bidder will be required to pay the Bid form fee Rs. 2360/- (Including GST@ 18%) for downloaded forms from the website, Bid Security as applicable in Bid condition no. **6** and processing fee of Rs. 2950/- (Including GST@ 18%) of R.I.S.L. through three separate prescribed challans (*format enclosed in Annexure- I*) in any branch of the Punjab National Bank into Account no. 2246002100024414 throughout the country upto 30.05.2023 or through D.D. / Bankers Cheque in favour of M.D. RMSCL (tender fees and Bid Security) and MD, RISL (tender processing fees) physically in the office of RMSCL by 6.00 PM on 30.05.2023 The bidders shall submit/upload scanned copy of all the challans in Technical Bid. Bids will be opened only after ensuring receipt of Bid fees along with processing fees and Bid Security. **In the absence of Bid fees, processing fees and Bid security the Bids shall be rejected and shall not be opened.**

2. Eligibility Criteria for Empanelment :-

- (1) Drug Testing Laboratories should have valid Approval for carrying out test on drugs under the Drugs and Cosmetics Act, 1940 and Rules there under. Three years standing in the test & analysis of **drug items** and the lab shall be entitled for empanelment for the categories of items for which lab has bid and having approval. Bid is invited from approved Drugs Testing Laboratories situated in India.
- (2) *The laboratory should be GLP compliant under the provisions of Drugs and Cosmetics Act, 1940 and Rules there under and should hold schedule L-1 certificate or should have approval from Drug Control Department and NABL accreditation with proper scope of accreditation to undertake testing of drug items.*
- (3) The laboratory should have an average annual turnover of **not less than Rs. 50 Lakh** for past preceding three years (2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22).
Only audited accounts would be considered provisional accounts would not be considered in any case.
- (4) The lab should have undertaken test and analysis of drugs and supplies of similar nature of drugs for at least three government institutions/corporation/reputed manufacturers of drug formulations.
- (5) The lab should not stand banned / debarred or blacklisted by any State or Central Government or its Organizations or its procurement agencies on the due date of bid submission. If a bidder or an approved bidder will be found defaulter for concealing this fact, then following actions may be taken.
 - (i) **Bid rejection**
 - (ii) **Bid Security forfeiture**
 - (iii) **Agreement rejection**
 - (iv) **Performance Security forfeiture**
 - (v) **Blacklisting**
- (6) The laboratory and its responsible persons should not have been convicted under the provisions of applicable laws with regard to the activities and

conduct of the laboratory.

(7) The laboratory should have all necessary instruments/equipments/machines for testing of drugs with minimum three functional HPLC's.

3 TECHNICAL BID

The Bidder must furnish the following in technical bid.

- a. Bidders are allowed the option to quote for anyone item or more items as mentioned in bid (list of medicines proposed to be analyzed tested as at Annexure-VII).
- b. The bidders shall submit/upload in Technical Bid scanned copies of all the challans / DD/ BC of deposits of Bid form fees, RISL processing fee and Bid Security Money.
- c. Attested Photocopy of Analytical approval duly renewed up to date, issued by the State Licensing Authority.
- d. **Compliance of Schedule L-1 of Drugs & Cosmetics Rules, 1945 (GLP certificate) and Copy of NABL accreditation with scope for testing of drug formulations.**
- e. Documentary evidence of having analysed Drug and medical items for last three years with a statement in the proforma as given in Annexure III.
- f. Attested copy of certificate of GST registration.
- g. GST return 31.12.2022 or latest Months.
- h. Non- Conviction Certificate by the State Licensing Authority/ competent authority.
- i. Annual turnover statement for 3 year i.e. (2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22) certified by the practicing Chartered Accountant with UDIN No.
- j. Copies of the Balance Sheet and Profit and Loss Account for three years i.e. (2018-19, 2019-20 & 2020-21 or 2019-20, 2020-21 & 2021-22) duly audited or certified by the practicing Chartered Accountant. No provisional balance sheet or Profit and Loss account would be entertained.
- k. The following information in the form given in Annexure IV (a) to IV (d).
 - a) The list of permanent technical qualified personnel employed in the laboratory.
 - b) The list of sophisticated instruments available in the laboratory.
 - c) Micro Biological facilities available in the laboratory.

- d. List of Reference Samples along with their date of procurement and quantities.
- e. In the case of Non- Pharmacopoeial Products the Method of Analysis Should be appended to the Report, especially if the sample is declared as “Not of the Standard Quality”.
- l. A declaration in the proforma given in Annexure V duly signed and Notarized.
- m. Details of Laboratory in Annexure – VI.
- n. A copy of PAN issued by Income Tax Department.
- o. Documentary evidence for the constitution of the company / concern.
- p. At any time prior to opening of price bid, RMSC either at their own initiative or in response to clarification requested by prospective tender, may modify tender by issuing an amendment. Such amendments shall be uploaded on e-Proc site and will be part of the tender.
- q. A bidder has to fill up the checklist enclosed at Annexure VIII indicating the infrastructure and testing facilities available in the lab.

4 PRICE BID:

The price bid shall also be known as financial document and every bidder will be required to submit its price in excel format attached to the bid document (BOQ). **BOQ template must not be modified/ replaced by the bidder and the same should be uploaded after filling the relevant columns, else the bid is liable to be rejected for the particular item. Bidders are allowed to enter the bidder name and values only. The bidder should quote rate for the complete tests as applicable to the item. The rate for sterility test for sterile products should also be quoted separately at last entry of BOQ. Any type of uncalled clarifications on prices or rebates shall not be accepted.**

5 OPENING OF TECHNICAL BID AND FINANCIAL BID EVALUATION

The technical bids would be opened on scheduled date and time on eproc website i.e. <https://eproc.rajasthan.gov.in>. After technical evaluation physical inspection of the laboratories may be carried out by the designated team. Thereafter financial bids would be opened of those bidders who are found finally responsive on technical criteria. The acceptable rates for analysis will be decided and communicated accordingly.

6 **BID SECURITY**

The Bid Security Money Deposit shall be Rs. 20,000/- (Rs Twenty Thousand only) The Earnest Money Deposit shall be paid in through separate prescribed challans (format enclosed in Annexure-I) in any branch of the Punjab National Bank Account no. 2246002100024414 throughout country up to 30.05.2023 or through D.D. / bankers cheque in favour of M.D. RMSCL physically in the office of RMSC by 6.00 PM on 30.05.2023 Bid Security Deposit in any other form will not be accepted

The Bids submitted without sufficient Bid Security will be summarily rejected. The Bid Security will be forfeited, if the Bidder withdraws its Bid after last time & date fixed for receiving bids or in the case of a successful Bidder, if the Bidder fails to sign the contract agreement or fails to furnish the security deposit within the stipulated time.

Government undertaking PSU are exempted from Bid Security deposition on producing the certificate issued by the competent authority.

7 **GENERAL CONDITIONS**

1. The details of the Drugs, to be analysed shall be given in **Annexure VII**.
2. *The Bidder should quote the rates for complete analysis of each product and name of test to be performed, methodology to be used for each test. However wherever rates for individual test are demanded, they should be furnished accordingly in BOQ.*
3. The rates quoted should be exclusive of taxes, though the applicable taxes are to be mentioned separately.
4. The rates quoted and accepted will be binding on the Bidder for the stipulated period and on no account any revision will be entertained till the completion of the rate contract period including extensions, if any given.
5. Analytical Laboratory, which also has its manufacturing activity, if empanelled by RMSC, then Samples of its own manufacturing unit shall not be sent to its empanelled laboratory for testing.
6. The laboratory will not be permitted to outsource any test to any other laboratory.
7. RMSCL shall have the right to cause inspection of the laboratory by the members of its technical committee before opening of price bid and subsequently as and when considered appropriate and based on the finding, the Bidder may be disqualified or de-empanelled, as the case may be.
8. Conditional tender will not be accepted and rejected immediately.
9. *GST at applicable rate should be mentioned by the bidder where ever applicable.*

8. ACCEPTANCE OF BID

1. The Bid evaluation committee formed by Managing Director, Rajasthan Medical Services Corporation Ltd. will evaluate the Bid with reference to various criteria specified in bid document.
2. The Managing Director, Rajasthan Medical Services Corporation Limited reserves the right to accept or reject any BID for any one or more of the items Bided for, without assigning any reason.
3. The Managing Director, Rajasthan Medical Services Corporation Limited has the right to accept one or more bids depending on the volume of analytical work.

9. AGREEMENT

1. **The agreement with empanelled laboratories shall remain valid up to 30.06.2025. If Required period of contract can be extended upto 3 months on same rate, terms and condition without any prior consent of the bidder and shall be binding on approved bidder.**
2. **RMSCL will issue letters of Intent (LOIs) to successful bidders and bidders who are empanelled will have to execute an agreement on a non-judicial stamp paper of value Rs. 500 /- (Stamp duty to be paid by the Bidder), in favour of Managing Director, Rajasthan Medical Services Corporation Limited Jaipur within 15 days from the date of receipt of the intimation to them informing that their BIDs have been accepted. The format of agreement will be issued by RMSCL. (Annexure IX)**
3. The Bidder shall not, at any time, assign, sub-let or make over the contract or the benefit therefore or any part thereof to any other person or persons whatsoever.
4. All notices or communication relating to, or arising out of this agreement or any of the terms thereof shall be considered duly served on or given to the Bidder if delivered to him or emailed on its email address or left at the premises, places of business or abode.

10. PERFORMANCE SECURITY

1. The successful Bidders shall be required to pay a Performance Security of **Rs. 50,000/-** (Rs Fifty Thousand only) ***in the form of demand draft*** at the time of execution of the agreement. **Performance security will be refunded three**

month after expiry of rate contract subject to successful completion of services.

11. COMPLETE ANALYSIS & REPORTING CONDITIONS

1. (a) On empanelment and entrustment of the job, the Analytical Laboratory should furnish the test reports within:
 - i. **10 days from the receipt of the sample in case of Tablets, Capsules, Pessaries, Ointments, Powder and Liquid Oral Preparations (non – sterile products)**
 - ii. **21 days from the receipt of the sample in the case of I.V. Fluids and injectables and other items requiring test for sterility.**
- b) All the tests mentioned in IP/BP/USP/Drugs & Cosmetics Act. etc. including addendus, (as the case may be) should be carried out for each and every sample. The results obtained in the test should be mentioned in numerical value (wherever possible). However this condition will not apply when only specific testing is called for/desired on any particular sample. If any drug is not included in the pharmacopeia at the time of bid opening and letter on it is including in any pharmacopeia the drug should be tested as per pharmacopeia specification.
- c) Mentioning only “COMPLIES” or “PASSES” in the result column of the report would be treated as incomplete report, if the result has some numerical value.
- d) Every test report must have remarks either as “Standard Quality” or “Not of Standard Quality”. Any ambiguity/cutting in reports will not be accepted (clear mention of “standard quality or not of standard quality” should be stated in bold letters and crossing/cutting of one of these will not be accepted).
- e) Reports should be in A4 size (8.27” X 11.69”) paper of good quality.
- f) Report should be issued on form 39 A and should have S. no. , name of drug sample, code no., batch no., mfg. date, exp. date, description of tests, protocol of test specified & applied, findings & results obtained and should be signed by person-in-charge of testing. In case of Not of Standard Quality Reports the reports shall be release on Pink/Red colored paper for easy identification of NOSQ drugs.
- g) Reports should be attached along with Spectra / Chromatography data sheets, if applicable and it will be considered incomplete if spectra or

chromatograms are not attached.

2. All test reports of each batch of sample should be submitted to the RMSC in triplicate. In case of failure of a sample, the result should be communicated immediately to the Executive Director (Q.C.) through phone / e-mail and the report should be sent along with protocol.
3. If in any circumstances (like break down of instrument, non-availability of reference standard etc.) the Analytical Laboratory is unable to undertake analysis for a sample, the same should be reported within 24 hours of receipt of such a sample by phone or E-mail and the sample should be returned to the Executive Director (Quality Control), Rajasthan Medical Services Corporation Limited, Jaipur after taking necessary telephonic or mail consent. In case of inability of laboratory to undertake the testing, a penalty of 25% of testing charges applicable for that product / products will be recovered.
4. If placebo or standard test procedure of any product is required the same should be demanded within 48 hours with return request. Period lapsed/taken in providing placebo or standard testing procedure will be condoned from prescribed time limit for that sample.
5. If any sample is received in a damaged condition by the laboratory, the sample should not be analyzed and the information should be sent immediately to the E.D. (Quality Control), Rajasthan Medical Services Corporation Limited Jaipur by Fax or E-mail.
6. The Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representative(s) has / have the right to inspect the laboratories of the Bidders who have submitted BIDs, before taking any decision regarding empanelment. Similarly, the Managing Director, Rajasthan Medical Services Corporation Limited or his authorized representatives may also inspect any empanelled laboratory, at any point of time during the continuance of the BID and terminate / cancel its empanelment or any orders issued to the laboratory, not to entrust any further testing job to the laboratory based on facts brought out during such inspections.
7. The successful lab shall have to make own arrangement for collection of sample, from RMSC Headquarters.

8. It will be sole discretion of RMSCL to allot the samples to any empanelled lab in case when there are more than one lab approved for an item. (One or more Laboratories may be empanelled by this tender.)

12. PAYMENT PROVISIONS

1. No advance payment towards any analysis will be made to the empanelled Bidder.
2. No payment will be made for the incomplete analysis or incomplete report. Deliberate omission of any critical test will be viewed seriously and shall invite action against the laboratory as deemed fit by RMSCL.
3. Payments towards the analysis of Drugs will be made as per approved rate plus tax on it will be along with Tax at the prevailing rate as applicable at the time of payment.
4. **GST shall be applicable as per prevailing rates notified by the Government.**

13. PENALTIES

1. If the successful Bidder fails to execute the agreement and deposit security amount within the time specified or withdraws the BID after intimation of the acceptance of the BID or owing to any other reasons, is unable to undertake the contract, the empanelment will be cancelled and the Earnest Money amount deposited by the Bidder shall stand forfeited in favour of the Rajasthan Medical Services Corporation Limited. Such Bidder(s) will also be liable for all damages sustained by the Rajasthan Medical Services Corporation Limited due to breach of BID conditions. Such damages shall be assessed by the Managing Director, Rajasthan Medical Services Corporation Limited whose decision shall be final and binding.
2. After entering into Rate contract, if the laboratory does not as per the terms and conditions, it may be disqualified to participate in the BID for the period as decided by RMSCL.
3. To assess the correctness of the test results being given by the Empanelled laboratories, samples at random, would also be sent to the Government Analyst for testing and if any variation is found the result would be informed to empanelled laboratories. If there is any gross variation in the analytical reports furnished by the empanelled laboratories (either pass or fail) with Government

Lab for 3 times in assay test and 4 times for any other specification, in a year, the empanelled laboratory shall be considered for blacklisting for a period as considered proper after following the due process.

4. If it is revealed that the analytical Laboratory is involved in any form of fraud and collusion with the suppliers of Rajasthan Medical Services Corporation Limited, the Analytical Laboratory will be black listed for a period considered suitable. The Bidders shall also be liable for action under criminal law and the matter will be notified to the concerned Director of Drugs Control for suitable action against them under Drugs & Cosmetics Act & Rules.
5. The Managing Director, Rajasthan Medical Services Corporation Limited will be at liberty to terminate, the empanelment of any laboratory either wholly or in part at one month's notice without assigning any reasons. The Bidder will not be entitled for any compensation whatsoever in respect of such termination.
6. In all matters pertaining to the BID, the decision of the Managing Director, Rajasthan Medical Services Corporation Limited shall be final and binding.
7. (i) If the laboratory requires an extension in time for submission of test report, on account of occurrence of any hindrance it shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of *furnishing the test report*.
(ii) The Executive Director (QC)/ Drug Controller/ADC (QC) may extend the testing period with or without liquidated damages in case they are satisfied that the delay in the submission of test reports is on account of any hindrances, he shall apply in writing for extension on occurrence of hindrance but not after the stipulated date of submission of report. Reasons shall be recorded.
(iii) **Extension in testing period:-** In case of extension in the testing period with liquidated damages the recovery shall be made on the basis of following percentages of *testing charges* which the Bidder has failed to submit:-
 - (a) Delay upto one fourth period of the prescribed testing period; 2.5%

(b) Delay exceeding one fourth but not exceeding half of the prescribed testing period; 5%

(c) Delay exceeding half but not exceeding three fourth of the prescribed testing period; 7.5%

(d) Delay exceeding three fourth of the prescribed testing period; 10%

Note: Fraction of a day in reckoning period of delay in ***furnish the test report*** shall be eliminated if it is less than half a day. The maximum amount of liquidated damages shall be 10%.

iv. If, at any time during the continuance of this Agreement, the ***laboratory*** has, in the opinion of the Purchaser, delayed in submitting any test report, by the reasons of any riots, mutinies, wars, fire, storm, earthquakes, tempest or other exceptional cause, on a specific request made by the laboratory, the time for submitting test report may be extended by the ***RMSCL*** purely at his discretion for such period as may be considered reasonable. No further representation from the ***laboratory*** will be entertained on this account.

14. CORRECTION OF ARITHMETIC ERRORS:

Provided that a financial bid is substantially responsive, the procuring Entity will correct arithmetical errors during evaluation of Financial Bids on the following basis:

- (i) If there is a discrepancy between the unit price and the total price that is obtained by multiplying the unit price and quantity, the unit price shall prevail and the total price shall be corrected, unless in the opinion of the Procuring Entity there is an obvious misplacement of the decimal point in the unit price, in which case the total price as quoted shall govern and the unit price shall be corrected;
- (ii) If there is an error in a total corresponding to the addition or subtraction of subtotals, the subtotals shall prevail and the total shall be corrected; and.
- (iii) If there is a discrepancy between words and figures, the amount in words shall prevail, unless the amount expressed in words is related to an arithmetic error, in which case the amount in figures shall prevail subject to clause (a) and (b) above.

If the Bidder that submitted the lowest evaluated bid does not accept the correction of errors, its Bid shall be disqualified and its Bid Security shall be forfeited or its Bid Securing Declaration shall be executed.

15. GRIEVANCE REDRESSAL DURING EMPANELMENT PROCESS:

The Designation and address of the First Appellate Authority is MD, NRHM.

The Designation and address of the Second Appellate Authority is Secretary to Government, Medical & Health and Family Welfare, Govt. of Rajasthan.

i. Filing an appeal

If any Bidder or prospective bidder is aggrieved that any decision, action or omission of the Procuring Entity is in contravention to the provisions of the Act or the Rules of the Guidelines issued there under, he may file an appeal to First Appellate Authority, as specified in the Bidding Document within a period of ten days from the date of such decision or action, omission, as the case may be, clearly giving the specific ground or ground on which he feels aggrieved:

Provided that after the declaration of a Bidder as successful the appeal may be filed only by a Bidder who has participated in procurement proceedings:

Provided further that in case a Procuring Entity evaluates the Technical Bids before the opening of the Financial Bids, an appeal related to the matter of Financial Bids may be filed only by a Bidder whose Technical Bid is found to be acceptable.

ii. The Officer to whom an appeal is filed under Para (1) shall deal with the appeal as expeditiously as possible and shall Endeavour to dispose it of within thirty days from the date of the appeal.

iii. If the officer designated under Para (1) fails to dispose of the appeal filed within the period specified in Para (2), or if the Bidder or prospective bidder or the Procuring Entity is aggrieved by the order passed by the First Appellate Authority, the Bidder or prospective bidder or the Procuring Entity, as the case may be, may file a second appeal to second Appellate Authority specified in the Bidding Document in this behalf within fifteen days from the expiry of the period specified in Para (2) or of the date of

receipt of the order passed by the First Appellate Authority, as the case may be.

iv. Appeal not to lie in certain cases

No appeal shall lie against any decision of the Procuring Entity relating to the following matters, namely:-

- (a) Determination of need of empanelment;
- (b) Provision limiting participation of Bidders in the Bid process; (c) The decision of whether or not to enter into negotiations;
- (d) Cancellation of a empanelment process;
- (e) Applicability of the provisions of confidentiality.

v. Form of Appeal

- (a) An appeal under Para (1) or (3) above shall be in the annexed Form along with as many copies as there are respondents in the appeal.
- (b) Every appeal shall be accompanied by an order appealed against, if any, affidavit verifying the facts stated in the appeal and proof of payment of fee.
- (c) Every appeal may be presented to First Appellate Authority or Second Appellate Authority, as the case may be, in person or through registered post or authorised representative.

vi. Fee for filling appeal

- (a) Fee for first appeal shall be rupees two thousand five hundred and for second appeal shall be rupees ten thousand, which shall be non-refundable.
- (b) The fee shall be paid in the form of bank demand draft or banker's cheque of a Scheduled Bank in India payable in the name of Appellate Authority concerned.

vii. Procedure for disposal of appeal

(a) The First Appellate Authority or Second Appellate Authority, as the case may be, upon filling of appeal, shall issue notice accompanied by copy of appeal, affidavit and documents, if any, to the respondents and fix date of hearing.

(b) On the date fixed for hearing, the First Appellate Authority or Second Appellate

Authority, as the case may be, shall,-

- (i) Hear all the parties to appeal present before him; and

(ii) Peruse or inspect documents, relevant records or copies thereof relating to the matter.

(c) After hearing the parties, perusal or inspection of documents and relevant records or copies thereof relating to the matter, the Appellate Authority concerned shall pass an order in writing and provide the copy of order to the parties free of cost.

(d) The order passed under sub-clause (c) above shall be placed on the State Public procurement Portal.

16. COMPLIANCE WITH THE CODE OF INTEGRITY AND NO CONFLICT OF INTEREST:

Any person participating in a empanelment process shall-

- a) Not offer any bribe, reward or gift or any material benefit either directly or indirectly in exchange for an unfair advantage in procurement process or to otherwise influence the procurement process;
- b) Not misrepresent or omit misleads or attempts to mislead so as to obtain a financial or other benefit or avoid an obligation;
- c) Not indulge in any collusion, Bid rigging or any-competitive behaviour to impair the transparency, fairness and progress of the procurement process;
- d) Not misuse any information shared between the procuring Entity and the Bidders with an intent to gain unfair advantage in the procurement process;
- e) Not indulge in any coercion including impairing or harming or threatening to do the same, directly or indirectly, to any part or to its property to influence the procurement process;
- f) Not obstruct any investigation or audit of a procurement process;
- g) Disclose conflict of interest, if any; and
- h) Disclose any previous transgressions with any Entity in India or any other country during the last three years or any debarment by any other procuring entity.

17. Conflict of interest:-

The Bidder participating in a bidding process must not have a Conflict of Interest.

A Conflict of interest is considered to be a situation in which a party has interests that could improperly influence that party's performance of official duties or responsibilities, contractual obligations, or compliance with applicable laws and regulations.

- I. A Bidder may be considered to be in Conflict of interest with one or more parties in bidding process if, including but not limited to:
- a. Have controlling partners/shareholders in common; or
 - b. Receive or have received any direct or indirect subsidy from any of them; or
 - c. Have the same legal representative for purposes of the Bid; or
 - d. Have a relationship with each other, directly or through common third parties, that puts them in a position to have access to information about or influence on the Bid of another Bidder, or influence the decisions of the Procuring Entity regarding the bidding process; or
 - e. The Bidder participates in more than one Bid in a bidding process. Participation by a Bidder in more than one Bid will result in the disqualification of all Bids in which the Bidder is involved. However, this does not limit the inclusion of the same subcontractor, not otherwise participating as a Bidder, in more than one Bid; or
 - f. The Bidder or any of its affiliates participated as a consultant in the preparation of the design or technical specification of the Goods, Works or Services that are the subject of the Bid; or
 - g. Bidder or any of its affiliates has been hired (or is proposed to be hired by the Procuring Entity as engineer-in-charge/ consultant for the contract.

18. JURISDICTION

1. In the event of any legal dispute arising out of the BID such dispute would be subject to the jurisdiction of the Civil courts within the city of Jaipur only.+

19. APPLICABILITY OF RULES

Besides above conditions all the provisions of RTPP Act 2012 & RTPP Rules 2013 shall be applicable.

Managing Director
Rajasthan Medical Services Corporation

Annexure - 1

Customer Copy

CAUTION : USE "FCMBR" MENU OPTION IN FINACLE INSTEAD OF "TM"

Bank Copy

punjab national bank

DIST. NO.

Branch

Institute Name

Institute ID

Rajasthan Medical Services Corporation, Jaipur

RMSCJ - A/c No. 2246002100024414

Date of Deposit

DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit

Mobile No.

Select any one out of - Tender Fees/EMD/SD/Tender Processing fees/Others

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable	₹	Ps
Commission	0	0
Total amount	0	0

Amount (in words): ₹

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer



punjab national bank

DIST. NO.

Branch

Institute Name

Institute ID

Rajasthan Medical Services Corporation, Jaipur

RMSCJ - A/c No. 2246002100024414

Date of Deposit

DD MM YY

DETAILS OF THE SUPPLIER

Supplier Name

Tender Ref. No.

Type of Deposit

Mobile No.

Select any one out of - Tender Fees/EMD/SD/Tender Processing fees/Others

Cash Deposit:

Denomination	₹	Ps
1000 *		
500 *		
100 *		
50 *		
20 *		
10 *		
5 *		
Coins *		
Total		

Cheque Deposit:

Chq No	Date of Chq	Name of Bank	₹	Ps

Total fee payable	₹	Ps
Commission	0	0
Total amount	0	0

Amount (in words): ₹

Name of the Depositor

Signature

Address for communication

For Bank use only

Acknowledgement

Cashier/Officer

ANNEXURE- II
Ref. Clause No. 2 (3),
3(h)

ANNUAL TURN OVER STATEMENT

The Annual Turnover of M/s. _____ for the past three years are given below and certified that the statement is true and correct.

S.No.	Years	Turnover in Lacs (Rs)
1	2018-19	
2	2019-20	
3	2020-21	
Total		Rs. Lacs
Average turnover per annual		Rs. Lacs

Or

S.No.	Years	Turnover in Lacs (Rs)
1	2019-20	
2	2020-21	
3	2021-22	
Total		Rs. Lacs
Average turnover per annual		Rs. Lacs

Date:

Signature of Auditor/
Chartered Accountant

Seal:
UDIN No.

(Name in Capital)

ANNEXURE III
Ref. Clause No: 3 (e)

PROFORMA FOR PERFORMANCE STATEMENT
(for a period of last 3 years)

Name of the Laboratory :

Address: _____

Types of Samples Analysed No. of Samples Analysed during

(2018-19, 2019-20 and 2020-21 or 2019-20, 2020-21, 2021-22

01. Tablets / Capsules / Pessaries/Dry Powders

02. Injectables

03. Liquid Preparations

04. Ointments / Creams / Gels

05. Others (Specify)

06. Surgicals (Specify item names)

07. Sutures (Specify types)

08. Implants

09. Devices

Signature :

Date :

Name of the Lab :

Office Seal :

ANNEXURE – IV (a)
Ref. Clause No: 3 (j) (a)

PERSONNEL IN QC DEPARTMENT

Name of the Technical Staff approved by State Licensing Authority along with his Designation, Highest Qualification, Experience (Experience relevant to analysis of drug items)

Signature :

Date :

Name of the Lab :

Office Seal :

**LIST OF SOPHISTICATED EQUIPMENT/INSTRUMENT/APPARATUS
AVAILABLE IN THE LAB**

S.No.	Name of the Equipment	Make &	Date of	Date of
Approved	Instruments / Apparatus	Description	Installation	for testing
			last	of drugs
			Validation	from
	State			
	licensing			
	Authority			
	since.....			

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (C)
Ref. Clause No: 3(j) (c)

FACILITIES IN THE MICROBIOLOGICAL SECTION

I. LIST OF STOCK CULTURES AVAILABLE

II. LIST OF EQUIPMENT / APPARATUS AVAILABLE WITH DATE OF INSTALLATION, make and approval from State Licensing Authority to permit microbiological testing in the Lab.

Signature :

Name of the Lab :

Date :

Official Seal:

ANNEXURE – IV (d)
Ref. Clause No: 3(j) (d)

**LIST OF REFERENCES SAMPLES ALONG WITH THEIR DATE OF
PROCUREMENT AND QUANTITIES**

Signature :

Name of the Lab :

Date :

Official Seal:

Affidavit

(on Non Judicial Stamp of Rs.500/-)

ANNEXURE – V
Ref. Clause No: 3(k)

DECLARATION FORM

1. I (Name of the Bidder) S/O _____, Age _____, resident of _____, am proprietor /Partner/Director having our office at _____ and the approved drug testing laboratory at _____ do hereby declare that I have carefully read all the conditions of BID of Rajasthan Medical Services Corporation Ltd., Jaipur, for the BIDs floated for empanelment of approved drugs testing laboratories for analysis of drugs. (Rate contract for two years ending on **30.06.2025**) and shall abide by all the conditions set forth therein.
2. I further declare that I possess valid approval for testing of all the drug items for which Price Bid have been submitted by me/us in Cover B and permission on Form 37 have been obtained for testing of these items from State Licensing Authority where ever applicable.
3. That the approval to test drug items have been obtained on Form 37 bearing No. _____ which is valid/renewed up to _____.
4. That the Bidder firm is a proprietorship/Partnership/Pvt. Ltd./ltd. firm and following are the other partners/directors:-

S.No.	Name of Partner/Director	Age	Present & Permanent Address
-------	--------------------------	-----	-----------------------------

5. That our laboratory/Firm/Company does not stand blacklisted /debarred or banned on any ground either by Bid Inviting Authority or Govt. of Rajasthan on the date of bid submission.

Our laboratory/Firm/Company also does not stand blacklisted, debarred or banned on the ground of **wrong reporting of test results** or on the ground of submission of fake or forged documents or false information / facts, by any State or Central Government or by its central drug procurement agencies, on the date of bid submission for supply of drugs/medicines in India.

That I/We have carefully read all the conditions of bid in Ref. No.: F.02(377)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2023/921 Dated :-11.05.2023

6. That we have testing facilities as per testing parameters mentioned in respective pharmacopoeias (IP/BP/USP etc.) and quoted for products as given below:-

Sr No.	Quoted item Code No. (as per mention in Annexure-VII)
1.	For Example 2
2.	
3.	

7. For the empanelment of analytical testing laboratories for the test and analysis of DRUGS (Rate contract for two years ending on **30.06.2025**) for Rajasthan medical services corporation and accept all conditions of bid, including amendments if any.
8. I/ we hereby declare under Section 7 of Rajasthan Transparency in Public Procurement Act, 2012. that:
- a. I/we possess the necessary professional, technical, financial and managerial resources and competence required by the Bidding Document issued by the Procuring Entity;
 - b. I/we have fulfilled my/our obligation to pay such of the taxes payable to the Union and the State Government or any local authority as specified in the Bidding Document;
 - c. I/we are not insolvent, in receivership, bankrupt or being wound up. not have my/our affairs administered by a court or a judicial officer, not have my/our business activities suspended and not the subject of legal proceedings for any of the foregoing reasons;
 - d. I/we do not have, and our directors and officers not have, been convicted of any criminal offence related to my/our professional conduct or the making of false statements or misrepresentations as to my/our qualifications to enter into a procurement contract within a period of three years preceding the commencement of this procurement process, or not have been otherwise disqualified pursuant to debarment proceedings;
 - e. I/we do not have a conflict of interest as specified in the Act, Rules and the Bidding Document, which materially affects fair competition;
9. Our complete address for communication with phone no.:- -----

10. E mail address :- -----

11. Bank detail for e banking :-

Name of account holder

Full name of Bank with Branch

A/c no. with full digits.....

IFSC code

(Deponent)

Signature :

Date :

Name of the Lab :

Office Seal :

Verification

I.....S/o.....(Designation).....

Affirm on oath that the contents/information from para 1 to 11 as mentioned above, are true & correct to the best of my knowledge and nothing is hidden. I also declare on oath, that if any information furnished by me as above is found wrong, false, forged or fabricated; the Corporation will be at liberty to cancel the Bid and forfeiting the Bid Security deposit and or performance security, for which I shall be solely responsible and the laboratory / firm may be Debarred/Banned/ prosecuted for the same

(Name of Deponent & Signature)

ATTESTED BY NOTARY PUBLIC

DETAILS OF LABORATORY

1. Name of the Laboratory & Full Address :

 Phone No (landline) :

 Fax :

 E-mail :

2. Other Branches & their Address (if any) :

3. Whether the firm has it own manufacturing unit? :

 If yes give details of address, license number etc.

4. Date of Inception :

5. Approval No. & Date :

6. Issued by :

7. Valid up to :

8. Schedule L-1 certificate its no. and date of issue (GLP) :
 or
9. (i) NABL Accreditation no. & date
 (ii) Scope of Accreditation
 (iii) Its validity.
10. Name of the authorized signatory :

11. Specimen Signature of the authorized Signatory :

12. Names & Specimen Signatures of the Approved technical Staff who are authorized to sign the test reports :

ANNEXURE –VII
Ref: Clause no. 3 (a),7(1)

NOTE:-

- **Bidders have to mention quoted item code in annexure V for which have testing facility as per respective pharmacopoeias (IP/BP/USP etc).**

S. No.	Code No.	Name of item with specification
1	2	3
1.	2	Bupivacaine Hydrochloride in Dextrose Injection USP Each ml contains Bupivacaine Hydrochloride 5.0 mg, Dextrose 80.0 mg.
2.	4	Bupivacaine Injection IP 0.5%
3.	5	Drotaverine Hydrochloride Injection 40 mg/2 ml
4.	6	Halothane BP 250 ml
5.	7	Isoflurane USP
6.	8	Ketamine Injection IP 50 mg/ml
7.	9	Lignocaine Ointment 5%
8.	10	Lignocaine and Adrenaline Injection IP Each ml. Contains:- Lignocaine Hydrochloride IP 20 mg. Adrenaline IP 0.01mg
9.	12	Lignocaine Gel IP 2%
10.	13	Lignocaine Injection IP 2%
11.	14	Propofol Injection IP 10 mg/ ml
12.	15	Thiopentone Injection IP 0.5 gm
13.	19	Diclofenac Sodium Injection IP 25 mg/ ml (IM/IV use)
14.	20	Diclofenac Gastro Resistant Tablets IP 50 mg (Enteric Coated)
15.	21	Fentanyl Citrate Injection IP 50 mcg /ml
16.	22	Ibuprofen and Paracetamol Tablets IP Ibuprofen 400 mg +Paracetamol 325mg
17.	23	Ibuprofen Tablets IP 200 mg (Coated)
18.	24	Ibuprofen Tablets IP 400 mg (Coated)
19.	25	Morphine Sulphate Injection IP 10mg/ml
20.	26	Paracetamol Drops [Paediatric Paracetamol Oral Suspension IP] (Each ml contains Paracetamol 150 mg)
21.	27	Paracetamol Syrup IP 125 mg/5ml (40% Sugar base with strawberry flavour and carmoisine colour)
22.	28	Paracetamol Tablets IP 500 mg
23.	29	Paracetamol Injection 150mg/ml
24.	30	Pentazocine Injection IP 30mg/ml (IM/IV Use)
25.	32	Tramadol Capsules IP 50 mg
26.	33	Tramadol Injection 50 mg/ ml
27.	34	Adrenaline Injection IP 1mg/ml (IM/IV use)
28.	35	Betamethasone Tablets IP 0.5mg
29.	37	Chlorpheniramine Maleate Tablets IP 4 mg
30.	39	Dexamethasone Injection IP 8 mg/2ml
31.	40	Dexamethasone Tablets IP 0.5mg
32.	42	Hydrocortisone Sod. Succinate Injection IP 100 mg base / vial (IM/IV use)
33.	43	Hydroxyzine Tablets IP 25 mg
34.	44	Methyl Prednisolone Sodium Succinate for Injection USP 500 mg
35.	45	Pheniramine Injection IP 22.75mg/ml
36.	47	Prednisolone Tablets IP 5 mg
37.	48	Promethazine Syrup IP 5mg/5ml
38.	49	Promethazine Injection IP 25mg/ml
39.	50	Promethazine Tablets IP 25 mg
40.	51	Naloxone Injection IP 0.4mg/ ml
41.	52	Pralidoxime Chloride Injection IP 500mg
42.	53	Carbamazepine Tablets IP 200 mg
43.	54	Carbamazepine Tablets IP 100 mg
44.	56	Phenobarbitone Tablets IP 30 mg
45.	57	Phenytoin Injection IP 50mg/ml
46.	58	Phenytoin Oral suspension IP 25mg/ml
47.	59	Phenytoin Tablets IP 100 mg (Film Coated)
48.	61	Sodium Valproate Gastro resistant Tablets IP 200 mg
49.	62	Acyclovir Oral Suspension IP 400mg/5ml
50.	63	Acyclovir Tablets IP 200 mg

S. No.	Code No.	Name of item with specification
1	2	3
51.	64	Acyclovir Tablets IP 800 mg
52.	65	Albendazole Oral suspension IP 400 mg/10ml
53.	66A	Albendazole Tablets IP 400 mg (Colour: Sunset Yellow FCF in suitable Flavoured Base)
54.	67	Amikacin Injection IP 100 mg
55.	68	Amikacin Injection IP 500 mg
56.	69	Amoxycillin and Cloxacillin Capsules 250mg + 250 mg
57.	70	Amoxycillin and Potassium Clavulanate Tablets IP 500 mg + 125 mg
58.	71	Amoxycillin Capsules IP 250mg
59.	72	Amoxycillin Capsules IP 500mg
60.	73	Amoxycillin Dispersible Tablets IP 125mg
61.	74	Amphotericin B Injection IP 50 mg
62.	75	Ampicillin Injection IP 500 mg
63.	78A	Azithromycin Tablets 100 mg Dispersible Tablets
64.	79A	Azithromycin Tablets IP 250 mg
65.	80A	Azithromycin Tablets IP 500 mg
66.	82	Benzathine Benzylpenicillin Injection IP 6 lac units
67.	84	Cefixime Tablets IP 100 mg
68.	85	Cefixime Tablets IP 200 mg
69.	86	Cefoperazone and Sulbactam for Injection Cefoperazone Sodium eq. to Cefoperazone 1 g and Sulbactam Sodium eq. to Sulbactam 0.5 g (IM/ IV use)
70.	87	Cefotaxime Injection 1gm IP3
71.	88	Cefotaxime Injection IP 250 mg
72.	89	Ceftazidime Injection IP 1 gm
73.	90	Ceftazidime Injection IP 250 mg
74.	91	Ceftazidime Injection IP 500 mg
75.	93	Ceftriaxone Injection IP 1gm /vial
76.	94	Ceftriaxone Injection IP 250 mg/ vial
77.	95	Ceftriaxone Injection IP 500mg/vial
78.	96	Cephalexin Capsules IP 250 mg
79.	97	Cephalexin Capsules IP 500 mg
80.	98	Chloroquine Phosphate Injection IP 40mg/ml
81.	99	Chloroquine Phosphate Tablets IP 250mg (Eq to 155 mg of Chloroquine base) (Film Coated)
82.	100A	Chloroquine Phosphate Suspension IP 50 mg/5ml
83.	101	Ciprofloxacin Injection IP 200mg/100ml
84.	102	Ciprofloxacin Tablets IP 250 mg (Film Coated)
85.	103	Ciprofloxacin Tablets IP 500 mg (Film Coated)
86.	104	Clotrimazole Cream IP 2% w/w
87.	105	Clotrimazole Vaginal Tablets IP 500 mg
88.	106	Compound Benzoic Acid Ointment IP [Benzoic Acid 6%+ Salicylic Acid 3%]
89.	107	Co-trimoxazole Oral suspension IP Each 5 ml contains Trimethoprim 40 mg and Sulphamethoxazole 200 mg
90.	108	Co-trimoxazole Tablets IP Trimethoprim 40 mg and Sulphamethoxazole 200 mg
91.	110	Diethylcarbamazine Tablets IP 100 mg
92.	111	Doxycycline Capsules IP 100 mg
93.	114A	Fluconazole Tablets IP 150mg
94.	116	Gentamicin Injection IP 80mg/2ml (IM/ IV use)
95.	118	Itraconazole Capsules BP 100 mg
96.	119	Meropenem Injection IP 500 mg
97.	120	Metronidazole Injection IP 500 mg/100ml
98.	121	Metronidazole Benzoate Oral Suspension IP 100 mg of base/5ml
99.	122	Metronidazole Tablets IP 200 mg (Film Coated)
100.	123	Metronidazole Tablets IP 400 mg (Film Coated)
101.	124	Norfloxacin Tablets IP 400 mg (Film Coated)
102.	125	Ofloxacin Tablets IP 200 mg
103.	128	Primaquine Tablets IP 2.5 mg
104.	129	Primaquine Tablets IP 7.5 mg
105.	131	Quinine Dihydrochloride Injection IP 300 mg/ ml
106.	132	Quinine sulphate Tablets IP 300mg (Film Coated)
107.	133	Azathioprine Tablets IP 50 mg
108.	134	Bleomycin Injection IP 15 mg (Bleomycin Sulphate Injection 15 units)
109.	137	Cisplatin Injection IP 50 mg/50ml

S. No.	Code No.	Name of item with specification
1	2	3
110.	138	Cyclophosphamide Injection IP 200 mg
111.	139	Cyclophosphamide Injection IP 500 mg
112.	141	Cytarabine Injection IP 500mg
113.	142	Danazol Capsules IP 50 mg
114.	143	Daunorubicin Injection IP 20 mg
115.	144	Doxorubicin Injection IP 50 mg/ 25 ml
116.	146	Etoposide Injection IP 100 mg
117.	147	Flunarizine Tablets 5 mg
118.	148	Fluorouracil Injection IP 250 mg/ 5ml
119.	149	L-Asparaginase Injection 10000 IU
120.	150	Leucovorin Calcium Injection IP/Calcium Folate Injection IP 10 mg /ml
121.	151	Melphalan Tablets IP 5 mg
122.	152	Mercaptopurine Tablets IP 50 mg
123.	153	Methotrexate Injection IP 50 mg/ 2 ml
124.	154	Methotrexate Tablets IP 2.5 mg
125.	155	Paclitaxel Injection IP 260 mg
126.	156	Paclitaxel Injection IP 100 mg
127.	157	Tamoxifen Tablets IP 10 mg
128.	158	Vinblastine Injection IP 10mg
129.	159	Vincristine Injection IP 1 mg (Vial) / Vincristine Injection USP 1 mg/ml (Amp)
130.	160	Levodopa and Carbidopa Tablets IP [Levodopa 100mg + Carbidopa 10 mg]
131.	161	Levodopa 250mg and Carbidopa 25 mg Tablets IP
132.	162	Trihexyphenidyl Hydrochloride Tablets IP 2 mg
133.	163	Acenocoumarol Tablets IP 2 mg (Nicoumalone Tablets IP)
134.	165	Deferasirox Tablets 100 mg
135.	166	Deferasirox Tablets 500 mg
136.	167	Deferiprone Capsules 250 mg
137.	168	Deferiprone Capsules 500 mg
138.	169	Desferrioxamine Injection IP 500 mg / Vial (For I.M. Injection and I.V., S.C. Infusion)
139.	173	Ethamsylate Injection 250 mg/ 2ml (IM/IV)
140.	180	Vitamin K Injection Each ml Contains Menadione Sodium Bisulphite 10 mg Equivalent to 5.2 mg of Menadione. (Aqueous Solution)
141.	181	Amiodarone Tablets IP 100 mg
142.	182	Amiodarone Tablets IP 200 mg
143.	183	Amiodarone Hydrochloride Injection 50 mg/ml
144.	184	Amlodipine Tablets IP 2.5 mg
145.	185	Amlodipine Tablets IP 5 mg
146.	186	Atenolol Tablets IP 50 mg
147.	187	Atorvastatin Tablets IP 10 mg
148.	188	Clopidogrel Tablets IP 75 mg
149.	189	Digoxin Injection IP 0.25 mg/ml
150.	190	Digoxin Tablets IP 0.25 mg.
151.	191	Diltiazem Tablets IP 30 mg (Film Coated)
152.	192	Dobutamine Injection IP 250 mg (Vial) / Dobutamine Injection IP 250 mg/5ml (Amp) (Liquid form)
153.	193	Dopamine Hydrochloride Injection IP 40 mg/ml
154.	194	Enalapril Maleate Tablets IP 5mg
155.	195	Enalapril Maleate Tablets IP 2.5mg
156.	197	Isosorbide dinitrate Tablets IP 5 mg
157.	198	Isosorbide mononitrate Tablets IP 20 mg
158.	199	Lisinopril Tablets IP 5 mg
159.	200	Losartan Tablets IP 50 mg
160.	201	Magnesium Sulphate Injection IP 500mg/ml (50% w/v)
161.	203	Nifedipine capsules IP 5mg
162.	204	Nifedipine Tablets IP 10 mg (Sustained Release)
163.	205	Nitroglycerin Injection IP 5 mg/ ml
164.	207	Propranolol Tablets IP 40 mg
165.	211	Verapamil Tablets IP 40 mg (Film Coated)
166.	213	Acyclovir Cream IP 5%
167.	215A	Cetrimide Cream IP
168.	216A	Fusidic Acid Cream IP 2%
169.	217	Glycerin IP

S. No.	Code No.	Name of item with specification
1	2	3
170.	218	Liquid Paraffin IP
171.	219	Ointment containing : Lidocaine IP 3%, Zinc oxide IP 5% , Hydrocortisone IP 0.25%, Allantoin IP 0.5%
172.	220	Miconazole Nitrate Cream IP 2%
173.	221	Povidone Iodine Ointment 5%
174.	222	Povidone Iodine solution IP 5%
175.	223	Powder Neomycin Bacitracin with Sulphacetamide (Neomycin 5mg, Bacitracin 250 units, Sulphacetamide 60 mg)
176.	224	Silver Sulphadiazine cream IP 1%
177.	232	Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 60% (iodine conc = 292 mg/ml)
178.	233	Diatrizoate Meglumine and Diatrizoate Sodium Injection USP 76%w/v (iodine conc =370 mg/ml)
179.	241	Tropicamide Eye Drops IP 1%
180.	245	Formaldehyde Solution IP 1966 (34.5% - 38%)
181.	246	Gentian Violet Topical Solution USP 1%
182.	247	Gluteraldehyde solution 2 %
183.	248	Hydrogen Peroxide Solution IP 6% (20 Vol)
184.	249	Lysol (Cresol with Soap Solution) IP Cresol 50% + Soap 50%
185.	250	Povidone Iodine Scrub Solution / cleansing solution 7.5% w/v Povidone Iodine (suitable for hand wash)
186.	252	Surgical Spirit IP
187.	253	Acetazolamide Tablets IP 250mg
188.	254	Frusemide Tablets IP 40 mg.
189.	255	Furosemide Injection IP 10mg/ml (IM & IV use)
190.	256	Hydrochlorothiazide Tablets IP 12.5 mg
191.	257A	Mannitol Injection IP 20% w/v
192.	258	Spirolactone Tablets IP 25 mg
193.	259	Torsamide Tablets 10 mg IP
194.	260A	Antacid Tablets Formula: Each chewable Tablets contains Magnesium Trisilicate 250mg, Dried Aluminium Hydroxide Gel 120mg, Peppermint oil
195.	261A	Antacid Liquid Each 5ml contains Dried Aluminium Hydroxide Gel 250 mg, Magnesium Hydroxide 250mg, Activated polydimethyl siloxane 50mg
196.	262	Bisacodyl Tablets IP 5 mg
197.	263	Dicyclomine Tablets IP 10 mg
198.	264	Dicyclomine Injection IP 10 mg /ml
199.	265	Dicyclomine Hydrochloride Oral Solution IP 10mg /5ml
200.	266	Domperidone Suspension IP 5mg/5ml
201.	267	Domperidone Tablets IP 10 mg
202.	268	Hyoscine Butylbromide Injection IP 20 mg/ ml
203.	269	Loperamide Tablets IP 2 mg
204.	270	Metoclopramide Injection IP 10mg/2ml
205.	271	Metoclopramide Tablets IP 10 mg
206.	272	Omeprazole Capsules IP 20 mg
207.	273	Ondansetron Injection IP 2mg/ml
208.	274	ORS Powder IP
209.	275	Pantoprazole Injection BP 40 mg
210.	276	Ranitidine HCL Injection IP 50mg/2ml
211.	277	Ranitidine Tablets IP 150mg (Film coated)
212.	278	Sodium Phosphates Enema BP Each 100ml contains Sodium Dihydrogen phosphate Dihydrate 10%, Disodium Hydrogen Phosphate Dodecahydrate 8%
213.	280	Carbimazole Tabletss IP 5 mg (Film Coated)
214.	282	Clomifene Tablets IP 25 mg
215.	283	Clomiphene Tablets IP 50 mg
216.	284	Conjugated Estrogen Tablets USP 0.625 mg.
217.	285	Dinoprostone Cream/Gel 0.5 mg Dinoprostone in syringe
218.	286	Ethinylloestradiol Tablets IP 50 mcg
219.	287	Glibenclamide Tablets IP 5 mg
220.	288	Gliclazide Tablets IP 40 mg
221.	289	Glimepiride Tablets IP 2 mg
222.	290	Glimepiride Tablets IP 1 mg
223.	291	Glipizide Tablets IP 5mg
224.	293	Hydroxyprogesterone Injection IP 250mg/ ml

S. No.	Code No.	Name of item with specification
1	2	3
225.	295	Metformin Tablets IP 500 mg
226.	296	Norethisterone Tablets IP 5 mg
227.	297	Pioglitazone Tablets IP 15 mg
228.	298 A	Progesterone Injection IP 200 mg/ 2ml
229.	298 B	Progesterone Injection IP 200 mg/ 2ml(suspension form)
230.	301	Thyroxine Sodium Tablets IP 100mcg
231.	311	Atracurium Besylate Injection IP 10 mg/ml
232.	312	Glycopyrrolate Injection IP 0.2 mg/ml
233.	313	Midazolam Injection IP 1 mg/ml
234.	314	Neostigmine Injection IP 0.5 mg/ml
235.	317	Succinylcholine Injection IP 50 mg/ml (IV use)
236.	318	Valethamate Bromide Injection 8mg /ml
237.	319	Atropine Eye Ointment IP 1%
238.	320	Atropine Sulphate Ophthalmic Solution USP 1%
239.	321	Chloramphenicol Eye Drops IP 0.5%
240.	322	Ciprofloxacin Eye Drops 0.3% w/v IP
241.	323	Ciprofloxacin Ophthalmic Ointment USP 0.3%
242.	324	Hydroxypropylmethyl cellulose solution 20 mg/ ml
243.	330	Tobramycin and Dexamethasone Ophthalmic Suspension USP 0.3%+0.1%
244.	331	Tobramycin Eye Drops BP 0.3%
245.	332	Tobramycin Ophthalmic Ointment USP 0.3%
246.	333	Isoxsuprine Injection IP 5 mg/ml
247.	334	Isoxsuprine Tablets IP 20 mg
248.	335	Methylergometrine Injection IP 0.2mg/ml
249.	336	Methylergometrine Tablets IP 0.125 mg
250.	337	Misoprostol Tablets 200 mcg
251.	338	Oxytocin Injection IP 5 IU/ml
252.	339	Alprazolam Tablets IP 0.25 mg
253.	340	Alprazolam Tablets IP 0.5mg
254.	341	Amitriptyline Tablets IP 25mg Film Coated
255.	342	Chlordiazepoxide Tablets IP 10mg
256.	343	Chlorpromazine Tablets IP 100 mg (Coated Tablets)
257.	344	Chlorpromazine Tablets IP 25 mg (Sugar- Coated)
258.	345	Chlorpromazine Tablets IP 50 mg. (Coated Tablets)
259.	349	Diazepam Injection IP 10mg/2ml (IM/IV use)
260.	350	Diazepam Tablets IP 5 mg
261.	351	Escitalopram Tablets IP 10 mg
262.	352	Fluoxetine Capsules IP 20 mg
263.	353	Haloperidol Injection IP 5 mg/ml
264.	354	Haloperidol Tablets IP 1.5 mg
265.	355	Haloperidol Tablets IP 5 mg
266.	356	Imipramine Tablets IP 25 mg (Coated Tablets)
267.	357	Imipramine Tablets IP 75 mg (Coated)
268.	358	Lithium Carbonate Tablets IP 300 mg
269.	359	Lorazepam Injection IP 2 mg/ml
270.	360	Olanzapine Tablets IP 5 mg
271.	361	Risperidone Tablets IP 2 mg
272.	362	Risperidone Tablets IP 1 mg
273.	363	Sertraline Tablets BP 50 mg
274.	364	Trifluoperazine Tablets IP 5 mg (Coated)
275.	365	Aminophylline Injection IP 25 mg/ml
276.	366	Beclomethasone Inhalation IP 200 mcg/ dose
277.	367	Budesonide Nebulizer Suspension BP 0.25mg/ ml oasis
278.	368	Cough Syrup Each 5ml contains Chloropheniramine Maleate IP 3mg Ammonium Chloride 130mg, Sodium Citrate 65 mg, Menthol 0.5 mg, Syrup Q.S.
279.	369	Ipratropium Bromide Nebulizer Solution BP 250 mcg/ ml
280.	370	Salbutamol Tablets IP 4 mg
281.	371	Salbutamol Inhalation 100 mcg /dose
282.	372	Salbutamol Nebuliser Solution BP 5 mg/ml
283.	373	Salbutamol Tablets IP 2 mg
284.	374	Theophylline and Etofylline Injection (Anhydrous Theophylline 50.6mg + Etofylline 169.4 mg)

S. No.	Code No.	Name of item with specification
1	2	3
285.	375	Theophylline and Etofylline Tablets (Theophylline IP 23mg + Etofylline IP 77 mg)
286.	376	Theophylline Tablets 400 mg Sustained release/controlled release (Theophylline prolonged Release Tablets IP)
287.	377	Compound Sodium Lactate Injection IP
288.	378	Dextrose Injection IP 25 % w/v
289.	379	Dextrose Injection IP 10%
290.	380	Dextrose Injection IP 5%
291.	381	Multiple Electrolytes & Dextrose Injection Type I (Electrolyte 'P' Injection)
292.	382	Multiple Electrolytes & Dextrose Injection Type III IP Electrolyte "M" Injection (I.V.)
293.	383	Potassium Chloride Injection 0.15 gm/ml
294.	384	Potassium chloride Oral Solution U.S.P 500mg/ 5ml
295.	385	Sodium Chloride and Dextrose Injection I.P (0.9%+5%)
296.	386	Sodium Chloride Injection IP
297.	387	Ascorbic Acid Tablets IP 500 mg
298.	388	Calcium Gluconate Injection IP 10% (IV use)
299.	390	Ferrous Sulphate and Folic Acid Tablets IP Each film coated Tablets Containing Dried Ferrous Sulphate IP- equivalent to 100mg Elemental Iron and Folic Acid IP 0.5mg
300.	391	Ferrous Sulphate with Folic Acid Tablets (Paediatric) IP Each film coated Tablets Containing Dried Ferrous Sulphate IP- equivalent to 20mg Elemental Iron and Folic Acid IP 100 mcg.
301.	392	Folic Acid Tablets IP 5 mg
302.	393	Multivitamin Drops Each ml contains Vit-A -3000 IU, Vit-D3-300 IU, Vit-B1 -1mg, Riboflavine Phosphate Sodium -2mg, D-Panthenol -2.5mg, Niacinamide -10mg, Pyridoxine HCL-1mg, Cyanocobalamin 1mcg, Lysine HCL 10mg
303.	394	Multivitamin Tablets NFI Formula Sugar coated. Vit A 2500 IU, Vit B1-2mg, Vit- B6-0.5mg, Vit-C-50mg, Calcium Pantothenate-1mg, Vit-D3-200IU, Vit-B2 2 mg, Niacinamide-25mg, Folic Acid-0.2 mg
304.	395	Vitamin B Complex Injection NFI
305.	397	Vitamin-B complex Tablets NFI (prophylactic) B1- 2mg, B2- 2mg, B6-0.5mg, Niacinamide 25mg, Calcium pantothenate 1mg (With appropriate overages)
306.	398	Black Disinfectant Fluid (Phenyl) (As per Schedule "O" Grade – III
307.	399	Concentrated Solution for Haemodialysis B.P Acetate concentrate in 10 Litre Cans.
308.	401	Peritoneal Dialysis Solution IP
309.	402	Sodium Bicarbonate Injection IP 7.5% w/v
310.	404	Water for Injection I.P.
311.	405	Polygeline 3.5% Solution with electrolytes for I.V. Infusion
312.	409	Vitamin A Paediatric oral solution IP Vitamin A concentrate oil IP Each ml contains vitamin A 100000IU
313.	410	Labetalol Tablets IP 100mg
314.	411	Labetalol Hydrochloride Injection IP 20mg/4ml
315.	412	Ampicillin Capsules IP 500 mg
316.	413	Nitrofurantoin Tablets IP 100mg
317.	414	Hyoscine Butylbromide Tablets IP 10mg
318.	415	Drotaverine Tablets IP 40 mg
319.	416	Hydroxyethyl Starch (130/0.4) 6% w/v with Sodium Chloride 0.9% w/v Intravenous Infusion
320.	417	Cloxacillin sodium Injection IP 500 mg
321.	418	Betamethasone Sodium Phosphate Injection IP 4mg/ml
322.	419	Vecuronium Bromide for Injection BP 4 mg (Freeze Dried)
323.	420	Phenobarbitone Injection IP 200mg/ml
324.	421	Flurbiprofen Sodium Ophthalmic Solution USP 0.03% w/v / Flurbiprofen Eye Drops IP 0.03% w/v
325.	424	Lidocaine Hydrochloride Topical Solution USP 4%
326.	425	Fluconazole Eye Drops 0.3%
327.	427	Cephalexin Oral Suspension IP (Cephalexin Dry Syrup IP) 125 mg/ 5 ml
328.	428	Ofloxacin oral Suspension IP 50mg/ 5ml
329.	430	Tinidazole Tablets IP 300 mg (Film Coated)
330.	431	Tinidazole Tablets IP 500 mg (Film Coated)
331.	432	Salbutamol Syrup IP 2mg/ 5ml
332.	433	Ranitidine Tablets IP 300 mg (Film coated)
333.	436	Indomethacin Capsules IP 25 mg
334.	437	Diclofenac Prolonged Release Tablets IP 100mg
335.	438	Dicyclomine Hydrochloride and Activated Dimethicone suspension. Each ml contains:

S. No.	Code No.	Name of item with specification
1	2	3
		Dicyclomine Hydrochloride 10mg, Activated Dimethicone 40mg
336.	439A	Dicyclomine and Paracetamol Tablets (Dicyclomine Hydrochloride 20 mg + Paracetamol 325 mg Tablets)
337.	440	Dextromethorphan Hydrobromide Syrup IP 13.5mg / 5ml
338.	441	Calcium & Vitamin D3 Suspension (Each 5 ml contains Calcium Carbonate equivalent to elemental Calcium 250 mg, Vitamin D3 - 125 IU)
339.	442	Saline Nasal Solution (Drops / Spray) (Sodium chloride 0.65%)
340.	443	Clotrimazole mouth paint (Clotrimazole 1% w/v)
341.	444	Aspirin Gastro resistant Tablets IP Each enteric coated Tablets contains Acetyl Salicylic Acid 75 mg
342.	445	Beclomethasone, Neomycin, and Clotrimazole Cream (Beclomethasone dipropionate 0.025%, Neomycin sulphate 0.5% Clotrimazole 1%)
343.	446	Gamma Benzene Hexachloride Lotion 1% (Lindane lotion USP) (Lindane Application BP)
344.	447	Chlorhexidine Gluconate Solution 5%
345.	448	Iron and Folic Acid Suspension.
346.	449	Surgical Spirit IP
347.	450	Povidone Iodine Solution IP 5%
348.	451	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg
349.	452	Glipizide and Metformin Hydrochloride Tablets USP (Glipizide 5mg, Metformin Hydrochloride 500 mg)
350.	453	Glibenclamide and Metformin Hydrochloride (SR) Tablets [Glibenclamide 5mg, Metformin hydrochloride 500 mg (Sustained Release)]
351.	454	Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets IP {Metformin hydrochloride (Sustained Release) 500 mg, Glimipiride 1 mg }
352.	455	Metformin Hydrochloride (Sustained Release) and Glimperiride Tablets IP {Metformin hydrochloride (Sustained Release) 500 mg, Glimipiride 2 mg }
353.	456	Glimperiride, Pioglitazone and Metformin Hydrochloride (Sustained Release) Tablets Each Tablets contains Glimperiride 2mg, Pioglitazone 15mg, Metformin Hydrochloride(Sustained release) 500 mg
354.	457	Amlodipine and Enalapril Maleate Tablets (Amlodipine Besilate equivalent to Amlodipine 5mg, Enalapril maleate 5mg)
355.	458	Losartan Potassium & Amlodipine Tablets IP (Losartan Potassium 50 mg, Amlodipine Besilate eq. to Amlodipine 5mg)
356.	459	Losartan Potassium & Hydrochlorothiazide Tablets IP (Losartan Potassium 50 mg, Hydrochlorothiazide Tablets 12.5mg)
357.	460	Amlodipine and Lisinopril Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Lisinopril eq. to lisinopril (anhydrous) 5mg]
358.	461	Amlodipine and Atenolol Tablets [Amlodipine Besilate equivalent to Amlodipine 5 mg, Atenolol 50mg]
359.	462	Atenolol Tablets IP 25 mg
360.	463	Enalapril Maleate Tablets IP 10 mg
361.	464	Hydrochlorothiazide Tablets IP 25 mg
362.	465	Lisinopril Tablets IP 10 mg
363.	466	Lisinopril Tablets IP 2.5 mg
364.	467	Losartan Tablets IP 25 mg
365.	468	Piperacillin and Tazobactam for Injection IP 4 gm + 500 mg Piperacillin and Tazobactam Injection IP
366.	469	Prednisolone Tablets IP 10 mg
367.	470	Prednisolone Tablets IP 20 mg
368.	472	Zinc Sulphate Dispersible Tablets IP Elemental Zinc 10 mg
369.	473	Amoxicillin Oral Suspension IP (Dry Syrup) 125 mg/5 ml
370.	474	Carbamazepine Oral Suspension USP 100 mg/5ml
371.	475	Cefpodoxime Dispersible Tablets 50 mg
372.	476	Cephalexin Tablets 125 mg (Dispersible Tablets)
373.	477	Ibuprofen Oral Suspension BP/USP 100 mg/ 5 ml
374.	478	Metoclopramide Hydrochloride Syrup IP 5 mg/ 5ml
375.	479	Sodium Valproate Oral Solution IP 200 mg / 5 ml
376.	481	Meropenem Injection IP 1 gm
377.	482	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 300 mg Iodine/ml.
378.	483	Diclofenac Sodium and Paracetamol Tablets IP Diclofenac Sodium 50 mg + Paracetamol 325 mg
379.	484	Timolol Eye Drops IP 0.5% w/v

S. No.	Code No.	Name of item with specification
1	2	3
380.	485	Homatropine Eye Drops IP 2 %
381.	486	Travoprost Eye Drops IP 0.004%
382.	487	Brimonidine Tartrate and Timolol Maleate Eye Drops 0.15% + 0.5%
383.	488	Iron Sucrose Injection USP/BP 20mg/ml (For IV Use) Each ml contain: Ferric hydroxide in complex with Sucrose equivalent to elemental Iron 20 mg
384.	491	Sevoflurane
385.	492	Aceclofenac and Paracetamol Tablets Aceclofenac 100 mg and Paracetamol 325 mg
386.	493	Diclofenac Gel: Diclofenac Diethylamine 1.16%, Methyl salicylate 10%, Linseed oil 3% and Menthol 5%
387.	495	Etoricoxib Tablets IP 120 mg
388.	496	Mefenamic Acid Tablets BP 500 mg
389.	497	Anticold Syrup Each 5 ml contains Phenylephrine Hydrochloride 2.5mg , Chlorpheniramine maleate 1 mg, and Paracetamol 125 mg
390.	498	Cetirizine, Phenylephrine & Paracetamol Tablets Cetirizine 5 mg, Phenylephrine 10 mg & Paracetamol 325 mg
391.	499	Cetirizine Syrup IP 5 mg/ 5ml
392.	500	Acetylcystine Solution USP /BP (Injection) 200 mg/ ml
393.	502	Acyclovir Intravenous Infusion IP 250 mg
394.	503	Acyclovir Intravenous Infusion IP 500 mg
395.	504	Amikacin Injection IP 250 mg
396.	505	Amoxicillin and Potassium Clavulante Injection IP 600 mg
397.	506	Amoxicillin and Potassium Clavulante Injection IP 1.2 g
398.	507	Amoxicillin and Potassium Clavulante Oral Suspension IP 200 mg + 28.5 mg per 5 ml
399.	508A	Artesunate Injection 60 mg (I.M./I.V. Use) Each Combo Pack contains Artesunate Injection 60 mg Vial, Sodium Bicarbonate Injection IP 5% w/v (1 ml ampoule), Sodium chloride Injection IP 0.9% w/v (5 ml ampoule)
400.	509	Aztreonam Injection USP 500 mg
401.	510	Cefepime Injection IP 500 mg
402.	511	Cefixime Oral Suspension IP 25 mg/ ml (Paediatric Drops)
403.	512	Cefuroxime Axetil Tablets IP 250 mg
404.	513	Clindamycin Capsules IP 150 mg
405.	514	Clindamycin Capsules IP 300 mg
406.	515	Levofloxacin Tablets IP 250 mg
407.	516	Linezolid Tablets IP 600 mg
408.	517	Linezolid Injection 200 mg/ 100 ml
409.	518	Mefloquine Tablets IP 250 mg
410.	520	Ofloxacin and Ornidazole Tablets IP (Ofloxacin 200 mg and Ornidazole 500 mg)
411.	521	Ofloxacin Infusion IP 200mg/ 100 ml (in NaCl Injection)
412.	523	Vancomycin for Intravenous Infusion IP 500 mg
413.	524	Vancomycin for Intravenous Infusion IP 1 gm
414.	526	Carboplatin Injection IP 150 mg
415.	527	Carboplatin Injection IP 450 mg
416.	528	Cisplatin Injection IP 10 mg/ 10 ml
417.	529	Dacarbazine Injection 500 mg IP
418.	531	Gemcitabine for Injection 200 mg
419.	532	Gemcitabine for Injection 1 gm
420.	533	Ifosfamide Injection IP 1 gm
421.	534	Imatinib Tablets IP 400 mg
422.	536	Methotrexate Tablets IP 10 mg
423.	538	Oxaliplatin Injection IP 50 mg
424.	540	Bromocriptine Tablets IP 2.5 mg
425.	541	Betahistine Tablets IP 8 mg
426.	542	Betahistine Tablets IP 16 mg
427.	543	Cinnarizine Tablets IP 25 mg
428.	544	Cinnarizine Tablets IP 75 mg
429.	545	Tranexamic Acid Tablets IP/BP 500 mg
430.	546	Warfarin Sodium Tablets IP 5 mg
431.	547	Adenosine Injection IP 6 mg/ 2 ml
432.	548	Atorvastatin Tablets IP 40 mg
433.	549	Clopidogrel and Aspirin Tablets IP Clopidogrel 75 mg and Aspirin 75 mg
434.	550 A	Fenofibrate Tablets IP 200 mg
435.	550 B	Fenofibrate Capsules IP 200 mg
436.	552	Metoprolol Tablets IP 25 mg

S. No.	Code No.	Name of item with specification
1	2	3
437.	553	Metoprolol Succinate Extended Release Tablets IP 50 mg
438.	554	Noradrenaline Injection IP 2 mg/ml
439.	555	Prazosin Tablets (Extended Release) 2.5 mg
440.	556	Telmisartan Tablets IP 40 mg
441.	558	Betamethasone Dipropionate Cream IP 0.05%
442.	559	Betamethasone Lotion IP 0.05%
443.	560	Clindamycin Phosphate Gel USP 1%
444.	561	Clobetasol Propionate Cream BP 0.05%
445.	564	Glycerin IP
446.	565	Ketoconazole Cream BP 2%
447.	568	Permethrin Lotion 5%
448.	569	Permethrin Cream 5%
449.	570	Tretinoin Cream USP 0.025%
450.	571	Povidone Iodine Ointment USP 5%
451.	572	Povidone Iodine Solution IP 10%
452.	573	Silver Sulphadiazine Cream IP 1%
453.	574	Spirolactone Tablets IP 50 mg
454.	575	Finasteride Tablets IP 5 mg
455.	576	Tamsulosin HCl Tablets/Capsule 0.4 mg
456.	579	Flavoxate Tablets IP 200 mg (Coated Tablets)
457.	580	Chlorhexidine Mouthwash IP 0.2%
458.	581	Dental Gel: Choline salicylate 8.7%, Benzalkonium Chloride 0.01%, Lignocaine HCl 2% (flavoured gel base)
459.	582	Tooth Gel: Sodium Monofluorophosphate 0.7% and Potassium Nitrate 5% (in flavoured base)
460.	583	Gum Paint containg Tannic acid 2%, Cetrimide 0.1%, Zinc Chloride 1%
461.	584	Metronidazole 1% and Chlorhexidine gluconate 0.25% Gel
462.	585	Ciprofloxacin 0.3% and Dexamethasone 0.1% Ear Drops Ciprofloxacin and Dexamethasone Otic Suspension USP
463.	586	Clotrimazole 1% with Beclomethasone Dipropionate 0.025% Ear Drops
464.	588	Neomycin, Polymixin B and Hydrocortisone Ear Drops (Neomycin sulphate 3400 IU, Polymixin B Sulphate 10000 IU, and Hydrocortisone 10 mg per ml) Neomycin and Polymixin B Sulfate and Hydrocortisone Otic Solution USP
465.	589	Ceruminolytic Drops (Wax dissolving ear drops): Paradichlorobenzene 2%, Benzocaine 2.7%, Chlorbutol 5%, Turpentine oil 15%
466.	590	Domperidone Oral Drops IP 10 mg/ ml
467.	591	Drotaverine & Mefenamic Acid Tablets Drotaverine 80 mg and Mefenamic Acid 250 mg
468.	592	Lactic Acid Bacillus Tablets 60 million spores
469.	593	Lactulose solution USP/ BP 10 gm/ 15 ml or 3.35gm/5 ml
470.	594	Liquid Paraffin IP
471.	595	Ondansetron Orally Disintegrating Tablets IP 4 mg
472.	596	Pantoprazole 40 mg and Domperidone 30 mg SR Capsules Pantopazole as enteric coated pellets, and Domperidone as sustained release pellets
473.	597	Ursodeoxycholic Acid Tablets IP 300 mg
474.	598	Allopurinol Tablets IP 100 mg
475.	599	Hydroxychloroquine Sulphate Tablets IP 200 mg
476.	600	Leflunomide Tablets IP 10 mg (Film coated)
477.	601	Leflunomide Tablets IP 20 mg (Film coated)
478.	602	Sulfasalazine Gastroresistant Tablets IP 500 mg
479.	603	Gliclazide and Metformin Tablets Gliclazide 80 mg and Metformin Hydrochloride 500 mg
480.	604	Glucagon for Injection USP 1 mg
481.	605	Medroxyprogesterone acetate Tablets IP 10 mg
482.	607	Thyroxine Tablets IP 50 mcg
483.	608	Octreotide Injection 50 mcg/ ml
484.	610	Chlorzoxazone, Diclofenac Sodium & Paracetamol Tablets (Chlorzoxazone 250 mg, Diclofenac Sodium 50 mg & Paracetamol 325 mg)
485.	613	Carboxymethylcellulose Eye Drops 0.5%
486.	615	Mifepristone Tablets IP 200 mg
487.	616	Formoterol Fumerate and Budesonide Powder for Inhalation IP 6 mcg + 200 mcg
488.	617	Budesonide Powder for Inhalation BP 200 mcg
489.	618	Ipratropium Powder for Inhalation IP 40 mcg
490.	619	Terbutaline Tablets IP 2.5 mg
491.	620	Xylometazoline Nasal Drops IP 0.1 %

S. No.	Code No.	Name of item with specification
1	2	3
492.	621	Sodium Chloride Injection IP
493.	622	Calcium Carbonate & vitamin D3 Tablets IP (Elemental Calcium 500 mg, Vitamin D3- 250 IU)
494.	623	Cholecalciferol granules 60, 000 IU/ gm
495.	624	Mecobalamin Injection 500 mcg/ ml
496.	627	Pyridoxine Tablets IP 40 mg
497.	629	Thiamine Tablets IP 100 mg
498.	630	Calcitriol Capsules IP 0.25 mcg
499.	631	Alendronate Sodium Tablets IP 35 mg
500.	632	Mannitol with Glycerin Injection 10% +10% w/v (For Intravenous Infusion)
501.	634	Pregabalin Capsules IP 75 mg
502.	636	Ramipril Tablets IP 2.5 mg
503.	638	Neostigmine Injection IP 2.5 mg/5 ml
504.	639	Oseltamivir Capsule IP 75 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 75mg]
505.	640	Oseltamivir Capsule IP 45 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 45mg]
506.	641	Oseltamivir Capsule IP 30 mg [Each Capsule contains Oseltamivir Phosphate equivalent to Oseltamivir 30 mg]
507.	642	Oseltamivir Phosphate for Oral Suspension IP 12 mg/ml. [Each ml contains 12 mg Oseltamivir base after reconstitution]
508.	644	Vitamin K1 (Phytomenadione) Injection 1 mg/0.5 ml Ampoule (aqueous Preparation) Each Pack contains:(i) One 0.5 ml Ampoule of Vitamin K 1(ii) One 1 ml disposable syringe with one 26 gaze needle
509.	645	ACT Containing 3 Tablets of Artesunate (each Tablets of artesunate 25mg strength) and 1 Tablets of Sulphadoxine Pyremethamine (250mg+12.5mg)
510.	646	ACT Containing 3 Tablets of Artesunate (50mg each) and 1 Tablets of Sulphadoxine Pyremethamine (500+25)mg
511.	647	ACT Containing 3 Tablets of Artesunate (100mg each) and 1 Tablets of Sulphadoxine Pyremethamine (750+37.5)mg
512.	648	ACT Containing 3 Tablets of Artesunate 150mg and 2 Tablets of Sulphadoxine and Pyremethamine (500mg+25mg)
513.	649	ACT Containing 3 Tablets of Artesunate (each 200 mg) and 2 Tablets of Sulphadoxine Pyremethamine (750+37.5mg) each or 3 Tablets Sulphadoxine Pyremethamine (500+25mg) each
514.	650	Glyceryl Trinitrate Tablets 2.6 mg Controlled Release tablets
515.	651	Artemether and Leumefantrin Tablets (80 mg + 480 mg)
516.	652	Methylcobalmine 500 mcg Tablets
517.	653	Methylcobalmine 1500 mcg Tablets
518.	654	Atropine Sulphate Injection IP 0.6 mg/ml (SC/IM/IV use)
519.	655	Fentanyl Citrate Injection IP 50 mcg/ml
520.	656	Naproxen Tablets IP 500 mg
521.	657	Naproxen Tablets IP 250 mg
522.	658	Etoricoxib Tablets IP 90 mg
523.	659	Levocetizine Tablets IP 5 mg
524.	660	Montelukast (10 mg) +Levocetizine (5mg) Tablets
525.	661	Sodium Valproate Tablets (Gastro Resistant) IP 500 mg
526.	662	Clobazam Tablets IP/Capsule 5 mg
527.	663	Clobazam Tablets IP/Capsule 10 mg
528.	664	Levetiracetam Tablets 500 mg IP
529.	665	Levetiracetam 100 mg/ml oral solution
530.	666	Levetiracetam Injection 500 mg/5ml USP
531.	667	Gabapentin Tablets IP 100 mg
532.	668	Gabapentin Cap IP 300 mg
533.	669	Co-trimoxazole Tablet IP (Trimethoprim 160mg+Sulphamethoxazole 800mg)
534.	670	Coal tar 6% & Salicylic Acid 3% Ointment
535.	671	Calamine Lotion IP
536.	672	Iohexol USP (Solution for Injection) Non Ionic contrast medium in Sterile aqueous solution 350 mg Iodine/ml.
537.	674	Quetiapine Tablets IP 50 mg
538.	675	Quetiapine Tablets IP 25 mg
539.	676	Vitamin D3 Oral Solution 60000 IU
540.	677	Cyclosporine Capsules IP 50 mg

S. No.	Code No.	Name of item with specification
1	2	3
541.	678	Clonazepam Tablets IP 0.5 mg
542.	679	Aspirin Tablets IP (Gastro-resistant) 150 mg
543.	682	Teneligliptin Tablets IP 20 mg
544.	683	Aztreonam Injection USP 1 gm
545.	684	Framycetin Sulphate Cream 1%
546.	685	Framycetin Sulphate Cream 1%
547.	686	Artemether and Leumefantrin Tablets (40 mg + 240 mg)
548.	687	Concentrated Solution for Haemodialysis B.P Sodium Hydrogen carbonate concentrate in 10 Litre Cans.
549.	692	Cough Syrup/Expectorant Each 5ml contains Ambroxol 15mg, Terbutaline Sulphate IP 1.5mg, Guaphenesin IP 50mg, Menthol IP 1mg.
550.	791	Intravenous Fat Emulsion 20% w/v 250ml
551.	797	Tab Dasatinib 100mg
552.	448W	Iron And Folic Acid Syrup IP
553.	489B	Iron and folic Acid tablet Each sugar-coated tablet containing 60mg elemental iron+500mcg folic acid, , blue colour
554.	490R	Iron and folic Acid tablet each Sugar-coated tablet containing 60mg elemental Iron+500mcg folic Acid, red colour
555.	490W	Iron And Folic Acid Tablets (Wifs Junior)
556.	NE1	Buprenorphine 2mg + Naloxone 0.5 mg Tablets
557.	NE2	Misoprostol Tablets IP 200 mcg
558.	NE11	Post exposure prophylaxis drugs for HIV- Drug Combination : Tenofovir 300 mg+ Lamivudine 300 mg + Efavirenz 600 mg IP
Biological Items		
559.	171	Dried Human Anti haemophilic Fraction IP (Dried Factor VIII Fraction IP) 250 IU/ Vial (IV use)
560.	175	Human Albumin Solution IP 20%
561.	176	rh-Erythropoetin Inj IP 10000 IU
562.	177	rh-Erythropoetin Inj IP 2000IU
563.	179	rh-Erythropoetin Inj IP 4000 IU
564.	209	Streptokinase Injection 15 lac units IP
565.	225	Anti A Blood Grouping Serum IP(Anti A Monoclonal Serum)
566.	226	Anti B Blood Grouping Serum IP(Anti B Mono Clonal Serum)
567.	227	Anti D(Rh) Blood Grouping Serum IP/Anti D Blood Grouping Serum IP
568.	242	VDRL Antigen (with + ve and - ve control) / RPR Slide Kit
569.	279	Biphasic Isophane Insulin Inj IP (30 % soluble insulin and 70 % isophane insulin) inj. 40 IU/ml(R-DNA Origin)
570.	294	Isophane Insulin Inj IP 40 IU /ml
571.	300	Insulin Injection IP (Soluble Insulin/Neutral Insulin Injection)40 IU/ml(r.DNA origin)
572.	303	Human Anti D Immunoglobulin Injection IP 300mcg (IM use)
573.	304	Human Anti D Immunoglobulin IP 150 mcg / Human Anti D Immunoglobulin 150 mcg
574.	305	Human Rabies Immunoglobulin Inj IP 150 IU/ ml
575.	306	Rabies Vaccine Human (Cell Culture) IP (Intradermal) 2.5 IU
576.	307	Rabies Vaccine Human (Cell Culture) IP (Intramuscular) 2.5 IU/ dose
577.	308	Snake Venum Anti Serum IP (Lyophilized)Polyvalent Anti Snake Venum,Serum Enzyme Refined.Contain purified equine globulins.1 ml of serum neutralizes 0.6 mg of cobra venum,0.45 mg of common kraite(Bungaras)venum(Details in RC)
578.	309	Tetanus Immunoglobulin IP 250 IU/ Vial
579.	310	Tetanus Vaccine (adsorbed) IP 5 ml vial
580.	406	Factor IX Concentrate (Purified) IP 500-600 I.U.(Human Coagulation Factor IX)
581.	407	Anti Inhibitor Coagulation Complex (Human Plasma Protein with a Factor VIII Inhibitor Bypassing Activity of 500 I.U. per Vial)
582.	408	Rabies Antiserum IP (Equine) 300 units per ml contains equine anti-rabies immunoglobulin fragments (I.M./SC use)
583.	480	Diphtheria Antitoxin IP 10000 IU
584.	525	Alpha Interferon Injection Interferon Alpha 2 concentrated Solution IP 3 Million Unit
585.	530	Filgrastim Injection IP (Granulocyte Colony Stimulating Factor) (SC/IV use) 300 mcg
586.	557	Urokinase Injection 5 Lac Unit (Lyophilized)
587.	633	Normal Human Intravenous immunoglobulin IP5g/100ml
588.	635	Surfactant for intratrecheal instillation (natural bovine lung surfactant)
589.	680	Insulin Glargine 3ml IP (100IU/ml) with 15 Insulin Syringes and needles/Cartridge 3ml (100IU/ml) with 15 needles and 1 pen per 20 cartridges
590.	688	Dried Factor VIII Fraction IP (IV use) 500 IU/Vial

S. No.	Code No.	Name of item with specification
1	2	3
591.	689	Dried Factor VIII Fraction IP (IV use) 1000 IU/Vial
592.	690	Recombinant Coagulation Factor VIIa 1mg
593.	691	Recombinant Coagulation Factor VIIa 2mg
594.	693	Insulin Glargine IP 10 ml vial (100 IU/ml) with 30 Insuline syringes with Needle
595.	734	Bevacizumab Injection 400 mg
596.	735	Bevacizumab Injection 100 mg
597.	748	Recombinant F IX 500 IU with diluent
598.	749	3rd Generation Recombinant F VIII 250 IU with diluent
599.	750	3rd Generation Recombinant F VIII 1000 IU with diluent
600.	767	Hepatitis B Immunoglobulin Injection IP 200 I.U
601.	774	Human Chorionic Gonadotropin Injection IP 5000 I.U.
602.	796	Inj Poractant Alpha 80 mg/ml in pack of 1.5 ml (Detail in RC)
603.	798	Human Immunoglobulin Inj with 12%IgM,12%IgA,76%IgG in pack of 10ml(0.5gm)
604.	NRD-147	Adalimumab 40 mg Inj.
605.	NRD-151	Prostaglandin 500MCG/ml Inj. 1 ml vial
606.	NRD-158	Avelumab 200 mg Inj.
607.	NRD-164	Botulinum Toxin Type A for injection 100 IU
608.	NRD-165	Botulinum Toxin Type A for injection 50 IU
609.	NRD-190	Cetuximab 100 mg Inj.
610.	NRD-191	Cetuximab 500mg Inj.
611.	NRD-202	Daratumumab 100 mg Inj.
612.	NRD-203	Daratumumab400 mg Inj.
613.	NRD-204	Darbepoietin Alfa 100mcg Inj.
614.	NRD-205	Darbepoietin Alfa 200 mcg Inj.
615.	NRD-206	Darbepoietin Alfa 500mcg Inj.
616.	NRD-211	Degludec insulin 100IU/ml Injection 3ml
617.	NRD-212	Denosumab 120 mg Inj.
618.	NRD-214	Detemir Insuline 100IU/ml Injection 3ml
619.	NRD-222	Durvalumab 120 mg Inj.
620.	NRD-223	Durvalumab 500mg Inj.
621.	NRD-244	FSH 75 IU Inj.
622.	NRD-252	Horse ATG(Anti Thymocyte Globulin) 250 mg Inj.
623.	NRD-253	HP HMG (Highly Human Menopausal parodied Gonadotropin) 150 IU Inj. IP
624.	NRD-257	Inotuzumab Ozogamicin Injection 1mg
625.	NRD-258	Insulin Aspart IP 100IU/ml Injection 3 ml
626.	NRD-260	Insulin Glulisine (Monocomponent Insulin Glulisine) 100 IU/ml Injection 3 ml
627.	NRD-261	Insulin Lispro IP Injection
628.	NRD-262	Interferon Beta 1 a Injection IP 30mcg
629.	NRD-306	Natalizumab 300 mg Inj.
630.	NRD-312	Nimotuzumab 50 mg Inj.
631.	NRD-321	Omalizumab 150 mg vial Inj.
632.	NRD-326	Peg Asparaginase 3750 IU 5 ml Inj.
633.	NRD-327	PEG filgrastim injection 6mg Inj.
634.	NRD-332	Pertuzumab injection 600 mg and Transtuzumab 600 mg in 10 ml
635.	NRD-346	Ranibizumab Injection (10mg/ml) 2.3mg/0.23ml per vial
636.	NRD-347	Rasburicase 1.5 mg Inj.
637.	NRD-348	Recombinant FSH 150 IU Inj.
638.	NRD-349	Recombinant FSH 300IU Inj.
639.	NRD-351	Recombinant LH 75IU Inj.
640.	NRD-352	Reteplase 18 mg Inj.
641.	NRD-355	Rituximab 100 mg Inj. IP
642.	NRD-356	Rituximab 500 mg Inj. IP
643.	NRD-359	Romiplostim 250 mcg Inj.
644.	NRD-360	Romiplostim 500 mcg Inj.
645.	NRD-363	Secukinumab 150 mg Inj.
646.	NRD-373	Tenecteplase 20mg Inj.
647.	NRD-374	Tenecteplase 40 mg Inj.
648.	NRD-385	t PA 20mg Alteplase for Injection
649.	NRD-386	t PA 50mg Alteplase for Injection
650.	NRD-389	Trastuzumab 440 mg Inj.
651.	NRD-390	Trastuzumab150Mg Inj.
652.	NRD-403	Insulin Glargine 300 IU IP per ml Inj. IP 1 prefilled pen of 1.5ml

S. No.	Code No.	Name of item with specification
1	2	3
653.	NRD-490	Rabbit ATG (Anti Thymocyte Globulin) 25mg / 5ml Inj.
654.	NRD-823	Human Albumin 20% in 50 ml Vial Inj. IP
655.	NRD-824	Tetanus Vaccine (Adsorbed) IP in 0.5 ml Inj.
656.	NRD-889	Glycopegylated Extended Half Life Nonacog Beta Pegol F Ix 500IU
657.	NRD-890	Glycopegylated Extended Half Life Nonacog Beta Pegol F Ix 1000IU
658.	NRD-891	Glycopegylated Extended Half Life Factor VIII 500IU
659.	NRD-892	Glycopegylated Extended Half Life Factor VIII 1000IU

ANNEXURE –VIII
Ref: Clause no. 3 (p)

To fill up the remark column of the enclosed Performa to access the
existing facilities of your laboratories

A - General requirements and premises

S.N.	Details of the requirement	Remark
1	For Laboratory management a qualified individual known as quality manager or technical manager is appointment.	
2	The Laboratory is designed, contracted and maintained to prevent entry of insects and rodents besides cross contaminations ;	
3	Interior surface (wall, floor, and ceilings) are smooth and free from cracks, and permit easy cleaning and disinfection ;	
4	Adequate provision for space and equipment for carrying out necessary test is provided & also unities like water, power and gas ;	
5	Air ventilations system is provide to ensure dust free environments	
6	The laboratories provided with adequate lighting and ventilation, air conditioning to maintain satisfactory temperature and relative humidity	
7	The faculties of drainage system and to prevent water logging in the laboratory	
8	Tables tops is made of with acid, alkali and solvent resistant material	
9	Adequate space with proper storage conditions in the laboratory shall be provided for keeping Reference and working standards	
10	The air circulation is maintained in the area where sterility test is carried out as per Schedule M.	

B- Personal & Equipment

S.N.	Details of the requirement	Remark
1	Staff in the laboratory shall possess necessary qualification, proper training and shall have Adequate, experience for the assigned duties.	
2	A training record of all the personal shall be maintained.	
3	Head of the laboratory must be high professional standing with experience in drug analysis and laboratories management	
4	The analytical instrument shall be housed in the dust-free environment and with controlled conditions of temperature and humidity	
5	A progress register for non functional equipments and action for procurement of spares and accessories, monitoring there of, shall be maintained	
6	A standard operating procedure for preventive maintenance of machine or equipment or apparatus shall be prepared by the laboratory	
7	Equipments such as burette, pipettes, volumetric flasks, weight boxes, thermometers etc. shall be thoroughly checked for accuracy for calibration before acceptance of use	
8	Equipments, instruments giving anomalous results or defective must be labeled as out of order	
9	Autoclaves must meet the requirements described for operations, safety and validation procedures	
10	Work involving the evolution of harmful and obnoxious vapors shall be carried out in a fume cupboard	

Chemicals and Reagents, Good housekeeping and safety

S.N.	Details of the requirement	Remark
1	All reagents and solutions in the laboratory shall be property identified with a label.	
2	A standardization register shall be maintained, with its raw date and SOP for preparation and standardization on stock solutions, standard solutions and volumetric solutions.	
3	Containers of stock solutions and of standard solutions shall bear the details.	
4	The storage and handling of chemicals and reagents shall be done in a manner considering the physicochemical properties substances and the hazard involved in their use.	
5	General and specific written down instructions for safety shall be circulated to each staff member.	
6	SOP for safety, house-keeping and loss prevention.	
7	Drinking, eating and smoking shall not be permitted in the laboratories.	
8	Staff must wear laboratory coats or other protective clothing including gloves and face masks and eye protection wherever required	
9	The laboratories shall have adequate first aid kit and fire fighting equipments.	
10	Operators carrying out sterility tests shall wear sterilized garments including headgear, face masks and shoes.	
11	The staff must be educated in the first aid techniques, emergency care and use of antidotes.	
12	Safety rules in handling cylinders of compressed gases must be observed and staff must be familiar with relevant colors identification codes ;	
13	Protective Precautions - 1- water showered 2- Rubber suction bulbs must be used on manual and siphons ; 3- Warnings, precautions and written Instructions violent, uncontrollable or reactions. 4- Appropriate facilities for the collection, storage and disposal of wasters. 5- Safe disposal of corrosive or dangerous products by neutralization or deactivation. 6- Safety precautions to be adopted while handling potassium cyanide and bromide ; 7- SOP for handling, collection, disposal of chemical and biological wastes.	

Maintenance, calibration, and validation of equipment & Reference materials : Microbiological Cultures :

S.N.	Details of the requirement	Remark
1	All equipments, instruments and other devices used in the laboratory shall use appropriate methods and procedures for all tests or calibrations and they shall be regularly Calibrated and validated.	
2	For most of the equipments and instruments, SOP for calibration and calibration schedule be the laboratory and a logbook shall also be prepared by each laboratory for proper documentation of calibrations results.	

3	Reference material shall be traceable to agency authorized by Government of India or any other International body.	
4	The laboratory shall prepare working standard by comparing with the reference standards and shall be routinely checked for their purity.	
5	Whenever, any new reference material is received by the laboratory following details are to be written - a- Source of supply ; b- Code number of the reference material ; c- Date of receipt ; d- Batch number or identification number of the supplying agency ; e- Details like assay value, water content or information provided ; f- Storage condition of the material ; g- Date of expiry, if any and date of manufacturing if possible.	
6	SOP for maintenance of microbial culture and sub-culture must be prepared by the laboratories ;	

Quality system : & internal quality audits, management review :

S.N.	Details of the requirement	Remark
1	The measurements and calibrations shall fully conform to the compendia requirements and the method demonstrably based on validation protocols are followed.	
2	Remedial action o the observations by internal and external audits are taken appropriately	
3	Documented quality policy for the organization.	
4	Internal audits are done to assure the integrity of the analysis ad such audits shall be conducted periodically	
5	Each activity is audited at least once in a year.	
6	The quality manager shall maintain all the records of the analysis being conducted which includes test system, the type of analysis , date on which analysis is done	
7	Review yearly 1- Report or input 2- Matter arising from previous reviews ; 3- Report of external audits, if any ; 4- Surveillance report, if any ; 5- Result of proficiency testing ; 6- Complaints or feedback received from users 7- Details of in-house quality control checks ; 8- Need of amendment of the quality system and documentation ; 9- Introduction training of new staff.	

Standard operating Procedures

S.N.	Details of the requirement	Remark
1	Shall be written in a chronological order listing different steps leading to an analysis of drugs or calibration of an instruments ;	
2	Shall have SOP manuals and have periodic Review.	
3	Standard Operation Procedures for the followings are required (i) Sample handling and accountability ; (ii) Receipt identification, storage, mixing and method sampling of the test	

S.N.	Details of the requirement	Remark
	and control articles ; (iii) Record keeping, reporting, storage and retrieval of data ; (iv) Coding of different studies, handling of data including use of computerized data system ; (v) Operation of technical audit personnel in performing and reporting audits, inspections and final report reviews ; (vi) Routing inspection of cleaning maintenance, testing, calibration and standardization of instruments ; (vii) Action to be taken in respect of equipment failure ; (viii) Analytical data methods (ix) Health and safety protection ; (x) Date handling and storage retrieval ; (xi) Health and safety protection ; (xii) Animal room preparations ; (xiii) Animal care ; (xiv) Storage and maintenance of microbial cultures ; (xv) Maintenance of sterility room (i.e. constant maintenance and monitoring of Aseptic condition room) ; (xvi) Use and storage of reference standards ; (xvii) Procurement of stores and equipment ; (xviii) Monitoring of testing of samples ; (xix) Method of retention of unexpended samples, their location, maintenance and disposal ; (xx) Document control ; (xxi) Redressal of technical complaints ; (xxii) House- keeping (xxiii) Corrective and preventive action ; (xxv) Calibration manual. (xxvi) Training manual.	
4	Protocols and specification archive :- List of all the pharmacopeias a file on patent and proprietary medicines (non-Pharmacopeia) test methods to specification prepared and validated by the manufacturer. The test methods shall be submitted to the concerned Drug Control Authority.	
5	Raw data - Date integrity and security shall be maintained Original entry must be saved and the system shall trail for all data.	
6	Storage and archival ; The residual sample shall be retained in proper storage condition for a period of one year after the final report.	
7	The laboratory must establish and maintain procedures for the identification collection, indexing, retrieval, storage, maintenance, and Disposal of all quality documents.	
8	All the raw date, documentation, SOP, protocols and final reports are the be retained and there shall be archives of orderly storage and expeditious retrieval of all raw data, documentation, protocols, interim and final report.	
9	The condition under which the original documents are stored must ensure	

S.N.	Details of the requirement	Remark
	their security and confidentiality.	
10	Raw data on thermal paper might fade away with time ; therefore, a photocopy of the thermal paper shall be retained in the archive.	

Above mentioned information correct as per our record and if found incorrect, RMSC may take action against our firm and reject our bid.

Signature:

Name of the Lab:

Date:

Official Seal:

ANNEXURE –IX
Ref: Clause no. 9 (2)

AGREEMENT

This Deed of Agreement is made on this _____ day of _____ 2023 by M/s. _____ represented by its Proprietor/ Managing partner /Managing Director having its laboratory Premises at _____ (hereinafter referred to as “Service provider” which term shall include its successors, representatives, heirs, executors and administrators unless excluded by the Contract) on one part and Rajasthan Medical Services Corporation Ltd, represented by its Executive Director (P) having is office at Swasthya Bhawan, Tilak Marg, C-Scheme, Jaipur (hereinafter referred to as “The Purchaser” which term shall include its successors, representatives, executors assigns and administrator unless excluded by the Contract) on the other part.

Whereas the Service provider has agreed to test the Drugs and Medicines for RMSC with specifications mentioned in the Schedule attached here to and mentioned at the prices noted there

in and in the manner and under the terms and conditions here in after mentioned and where as the Service provider has deposited with the Purchaser a sum of Rs _____ (Rupees only) as Performance Security Deposit for the due and faithful performance of this Agreement, to be forfeited in the event of the Service provider failing duly and faithfully to perform it. Now these presents witness that for carrying duly and faithfully to perform it. Now these presents witness that for carrying out the said Agreement in this behalf into execution the Service provider and the Purchaser do hereby mutually covenant, declare, contract and agree each of them with the other of them in the manner following, that is to say,

The term “Agreement”, wherever used in this connection, shall mean and include the terms and conditions including amendments contained in the invitation to tender floated for the Empanelment of Analytical Testing Laboratories for the test and Analysis of Drugs for Rajasthan Medical Services Corporation Ltd F.02(377)/RMSCL/ED (P) EMPANELMENT/DTL/NIB-09/2023/921 Dated :- 11.05.2023 the instruction to Bidders, the conditions of Bid, acceptance of Bid, particulars hereinafter defined and those general and special conditions that may be added from time to time.

1. (a) The Agreement is for the test by the Service provider to the Purchaser of the testing of Drug and Medicines specified in the Schedule attached here to at process noted against each therein on the terms and conditions set forth in the Agreement.
- (b) This Agreement shall be deemed to have come into force with effect from the date of issuance of letter of acceptance no.and dated.....and it shall remain in force up to 30.06.2025 and extendable upto 3 months, if required. Firm shall be bound to accept the extension period of Rate Contract.

TERMINATION OF CONTRACT ON BREACH OF CONDITION

1. (a) In case the Service provider fails or neglects or refuse to faithfully perform any of the Covenants on his part herein contained, it shall be lawful for the Purchaser to forfeit the amount deposited by the Service provider as Performance Security and cancel the Contract.
- (b) In case the Service provider fails, neglects, or refuse to observe, perform, fulfill and keep, all or any one or more or any part of any one of the Covenants, stipulation and provisions herein contained, it shall be lawful for the Purchaser on any such failure, neglect or refusal, to put an end to this Agreement and thereupon every article, cause and thing herein contained on the part of the Purchaser shall cease and be void, and in case of any damage, loss, expenses, difference in cost or other moneys from out of any moneys for the time being payable to the Service provider under this and/or any other Contract and in case such last mentioned moneys are insufficient to cover all such damages, losses, expenses, difference in cost and other moneys as aforesaid, it shall be lawful for the Purchaser to appropriate the Performance Security made by the Service provider as herein before mentioned to reimburse all such damages, losses, expenses, difference in cost and other money as the Purchaser shall have sustained, incurred or been put to by reason of the

Service provider having been guilty of any such failure, negligence or refusal as aforesaid or other breach in the performance of this Contract.

(c) If at any time during the course of the Contract, it is found that any information furnished by the Service provider to the Purchaser, either in his Tender or otherwise, is false, the Purchaser may put an end to the Contract/Agreement wholly or in part and thereupon the provisions of Clause (a) above shall apply.

2. The Purchaser reserves the right to terminate without assigning any reasons therefore the Contract/Agreement either wholly or in part without any notice to the Service provider. The Service provider will not be entitled for any compensation whatsoever in respect of such termination of the Contract/Agreement by the Purchaser.

NOTICE ETC, IN WRITING

3. All Certificates or Notice or orders for time or for extra, varied or altered supplies which are to be the subject of extra or varied charges whether so described in the Agreement or not, shall be in writing, and unless in writing, shall not be valid, binding or be of any effect whatsoever.

SERVICE PROVIDER NOT HAVE ANY INTEREST IN THE OFFICERS CONCERNED AND SUBORDINATES

4. The Service provider shall not be in any way interested in or concerned directly or indirectly with, any of the Officers, Subordinate or Servants of the Purchaser. In any trade, business or transactions nor shall the Service provider give or pay or promise to give or pay any such Officer, Subordinate or Servant directly or indirectly any money or fee or other consideration under designation of "Custom" or otherwise; nor shall the Service provider permit any person or persons whomsoever to interfere in the management or performance hereof under power of attorney or otherwise without the consent in writing the consent in writing of the Purchaser obtained in first hand.

BANKRUPTCY OF THE SERVICE PROVIDER

5. In case the Service provider at any time during the continuance of the Contract becomes bankrupt or insolvent or commits any act of bankruptcy or insolvency under the provisions of any law in that behalf for the time being in force, or should compound with his creditors, it shall be lawful for the Purchaser to put an end to the Agreement, and thereupon every article, clause and thing herein contained to be operative on the part of the Purchaser, shall cease and be void and the Purchaser shall have all the rights and remedies given to him under the preceding clauses.

SERVING OF NOTICE ON SERVICE PROVIDER

6. All notice or communication relating to or arising out of this Agreement or any of the terms thereof shall be considered duly served on or given to the Service provider if delivered to him or left at his premises, place of business or abode.
7. And it is hereby agreed and declared between the parties hereto that in case any question of dispute arises touching the construction or wording of any of clause herein contained on the rights, duties, liabilities of the parties hereto or any other way, touching or arising out of the presents, the decision of the Managing Director, Rajasthan Medical Services Corporation Ltd in the matter shall be final and binding.
8. All disputes arising out of this agreement and all questions relating to the interpretation of this agreement shall be decide by the Govt. and the decision of the Govt. shall be final.

SERVICER PROVIDER
(Signature, Name & Full Address)

Executive Director (Procurement),
RAJASTHAN MEDICALSERVICES
CORPORATION LTD.

Witness (Signature, Name & Full Address)

- 1.
- 2.